The QualityStocks Daily Tuesday, Novemeber 19th, 2024

Today's Top 3 Investment Newsletters

QualityStocks(PRFX) $1.4000 +161.68%

MarketClub Analysis(SOAR) $0.4699 +122.70%

MarketBeat(ACRS) $4.5900 +46.18%

The QualityStocks Daily Stock List

Pain Reform (PRFX)

QualityStocks, StockEarnings, Schaeffer's, StreetInsider, MarketClub Analysis, BUYINS.NET, PennyStockScholar, PennyStockProphet, MarketBeat and INO Market Report reported earlier on Pain Reform (PRFX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Pain Reform Limited (NASDAQ: PRFX) is a clinical stage pharmaceutical firm that is focused on researching, developing and commercializing therapies that can be used to manage post-operation pain in Israel.

The firm has its headquarters in Tel Aviv, Israel and was founded in 2007. It offers technology which can be used to improve and prolong the efficacy of pain therapies, decrease adverse effects, enhance return of motor function and increase patients’ convenience.

The company’s strategy is to integrate generic drugs that have been proven effective and safe with its proprietary extended released drug-delivery system, which will allow the company to make use of the 505 (b)(2) regulated pathway established by the FDA and in turn, bring about huge improvements in therapy through extended release drug products. The regulated pathway may substantially decrease the future costs and time usually linked with clinical development.

Its product pipeline is made up of a viscous clear oil-based solution dubbed PRF-100, which offers extended and localized post-surgical analgesia and is administered directly into the surgical wound prior to closure. The candidate is based off of ropivacaine; which is a local anesthetic. It is currently undergoing a pair of phase three clinical trials to test its effectiveness in treating patients undergoing hernia repairs and bunionectomy surgeries.

Using the 505(b)(2) new drug application will allow the firm to introduce new drug formulations to the market, based on data developed by other companies. This will help extend the company’s reach by working with other firms, which will in turn boost investments into the company and its growth.

Pain Reform (PRFX), closed Tuesday's trading session at $1.4, up 161.6822%, on 195,809,291 volume. The average volume for the last 3 months is 1.11M and the stock's 52-week low/high is $0.4318/$20.16.

Exicure, Inc. (XCUR)

StockEarnings, QualityStocks, PCG Advisory, MarketBeat, StocksEarning, Premium Stock Alerts, StockMarketWatch, Timothy Sykes, The Online Investor, MarketClub Analysis, InvestorsUnderground, InsiderTrades, FreeRealTime and 360 Wall Street reported earlier on Exicure, Inc. (XCUR), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Exicure, Inc. is the pioneer in gene regulatory and immunotherapeutic drugs employing proprietary Spherical Nucleic Acid (SNA™) technology. A clinical-stage biotechnology company, it is developing therapeutics for neurology, immuno-oncology, inflammatory diseases, and also other genetic disorders based on its proprietary SNA technology. SNA™ technology originated in the lab of Professor Chad A. Mirkin at the Northwestern University International Institute for Nanotechnology. Established in 2011, Exicure has its corporate headquarters in Chicago, Illinois. The Company’s shares trade on the Nasdaq Global Select Market.

Exicure’s belief is that its proprietary SNA architecture has distinct chemical and biological properties, which may provide advantages over other nucleic acid therapeutics and may have therapeutic potential to target diseases not normally addressed with other nucleic acid therapeutics. The Company is in preclinical development of XCUR-FXN, an SNA–based therapeutic candidate, for the treatment of Friedreich’s ataxia (FA).

The design of Exicure's proprietary SNA™ architecture is to unlock the potential of therapeutic oligonucleotides in a broad array of cells and tissues. SNA constructs overcome one of the most difficult obstacles to nucleic acid therapeutics. This is safe and effective delivery into cells and tissues. The Company’s Intellectual Property (IP) portfolio includes greater than 135 pending patent applications and more than 60 allowed or issued patents.

Exicure’s pipeline also includes Cavrotolimod (AST-008). Cavrotolimod (AST-008) is a toll-like receptor 9 agonist. The design of it is to activate the innate immune system and induce a potent anti-cancer immune response, particularly in combination with checkpoint inhibitors.

Exicure, Inc. (XCUR), closed Tuesday's trading session at $5.82, up 47.7157%, on 3,705,293 volume. The average volume for the last 3 months is 14.032M and the stock's 52-week low/high is $1.44/$6.00.

Digital Brands Group (DBGI)

QualityStocks, StockEarnings, Premium Stock Alerts, BUYINS.NET, Schaeffer's, The Online Investor and InvestorPlace reported earlier on Digital Brands Group (DBGI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Digital Brands Group Inc. (NASDAQ: DBGI) is engaged in the provision of apparel under different brands on wholesale and direct-to-consumer basis.

The firm has its headquarters in Austin, Texas and was incorporated in 2012. Prior to its name change, the firm was known as Denim L.A. Inc. It operates as part of the retail and whole-discretionary industry, under the consumer discretionary sector, in the retail-discretionary sub-industry and serves consumers in the U.S.

The company operates through the Bailey 44 and DSTLD segments. It brings like-minded direct-to-consumer names under a single portfolio to share data, infrastructure and operational resources in an attempt to reduce redundant fixed costs that are expensive to maintain and difficult to establish. The elimination of administrative responsibilities for their brands allows innovation and creativity to be stimulated and enables brands to be committed to the product and customer experience.

The enterprise provides luxury men’s suiting under the ACE Studios brand and denims under the DSTLD brand. It is also involved in designing, manufacturing and selling women’s apparel, which includes rompers, jackets, sets, bottoms, jumpsuits, tops and dresses, under the Bailey 44 brand. It sells its products directly to the end consumer via its websites, as well as via its own showrooms, select department stores and wholesale channels in specialty stores.

Digital Brands Group (DBGI), closed Tuesday's trading session at $0.1166, up 17.8969%, on 72,261,669 volume. The average volume for the last 3 months is 16,130 and the stock's 52-week low/high is $0.0864/$12.80.

Aurora Mobile (JG)

MarketClub Analysis, MarketBeat, StockMarketWatch, QualityStocks, Early Bird, BUYINS.NET, StockEarnings, TradersPro, The Stock Dork, StreetInsider, InvestorPlace, INO Market Report and FreeRealTime reported earlier on Aurora Mobile (JG), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Aurora Mobile Limited (NASDAQ: JG) is a holding firm that is engaged in the provision of mobile data solutions platform to app developers in China.

The firm is based in Shenzhen, in the People’s Republic of China and was incorporated in 2014, on April 9th by Chen Fei and Wei Dong Lou. It offers its services to mobile app developers in a range of industries, including the healthcare, education, ecommerce, tourism, financial services, gaming, entertainment and media fields.

The company serves consumers in China and can gain access to huge amounts of anonymous and real-time device-level behavioral data. Their services can also be integrated into different apps on one device, which enables the firm to receive device-based data from multiple and different dimensions, both offline and online.

The enterprise provides location-based intelligence, financial risk management, market intelligence and targeted marketing services. Its data platform provides sharing, short message service, analytics, instant messaging, verification and push notification solutions. The enterprise also offers application programming interfaces that develop connectivity and automate the message exchange process between backend networks and mobile applications, as well as an interactive web-based service dashboard that enables application developers to monitor and use their services via controls on a continuous basis.

Aurora Mobile (JG), closed Tuesday's trading session at $5.07, up 18.4579%, on 43,279 volume. The average volume for the last 3 months is 7,945 and the stock's 52-week low/high is $1.85/$9.7756.

COSCIENS Biopharma (CSCI)

We reported earlier on COSCIENS Biopharma (CSCI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSE: CSCI) (FRA: ET8) is a specialty biopharmaceutical firm focused on the development and commercialization of diagnostic tests and therapeutics.

The firm has its headquarters in Toronto, Canada and was incorporated in 1990. Prior to its name change in August 2024, the firm was known as Aeterna Zentaris Inc. It operates as part of the biotechnology industry, under the healthcare sector. The firm serves consumers around the globe, with a focus on those in Canada, Germany, Denmark, the United States, Ireland and Switzerland.

COSCIENS Biopharma is party to a license agreement with Consilient Health Limited and NK MEDITECH Ltd. for the development and commercialization of macimorelin; and a license and research agreement with University of Wuerzburg to develop, manufacture, and commercialize AIM biologicals for the treatment of neuromyelitis optica spectrum disorder. It is also party to a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria Eood for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults, as well as the University of Sheffield for the development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of chronic hypoparathyroidism.

The enterprise’s lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications. Its other products include AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis.

COSCIENS Biopharma (CSCI), closed Tuesday's trading session at $3, off by 6.25%, on 27,821 volume. The average volume for the last 3 months is 195,625 and the stock's 52-week low/high is $2.8104/$11.10.

Innovative Industrial Properties Inc. (IIPR)

InvestorPlace, QualityStocks, Kiplinger Today, The Online Investor, Top Pros' Top Picks, Schaeffer's, Daily Trade Alert, MarketBeat, The Street, DividendStocks, Wealth Insider Alert, Trades Of The Day, The Wealth Report, Zacks, CannabisNewsWire, TradersPro, FreeRealTime, StreetInsider, Stock Up Featured, StockMarketWatch, The Street Report, Investopedia, Trading Concepts, Early Bird, CFN Media Group, Stock Gumshoe, Outsider Club, Marketbeat.com, StreetAuthority Daily, TipRanks, Inside Trading, VectorVest and Wealth Daily reported earlier on Innovative Industrial Properties Inc. (IIPR), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Public use would remain off-limits, ensuring that cannabis consumption is kept private and not visible in open areas. The measure specifically avoids creating a commercial cannabis market, unlike the recent ballot efforts in other states that sought to legalize the production and sale of marijuana.

Joe Evans, treasurer for Kind Idaho, highlighted this distinction in a statement back in September when the group first submitted the measure. He noted that the group’s approach is based on the belief that people should be allowed to manage their health and well-being privately, without interference from the state, as long as they’re acting responsibly.

Evans also mentioned that the straightforwardness of the measure might make it more appealing to Idaho voters as it does not include provisions for a state-managed medical cannabis program, which has been part of prior legalization efforts.

Kind Idaho has revised the proposal’s language following feedback from state officials, including the Idaho secretary of state and attorney general. The measure, titled “Decriminalize Marijuana Now,” has now entered the next phase of the state approval process.

The attorney general’s office has 10 days to finalize the ballot title and draft a summary for voters. Once this step is complete, Kind Idaho plans to start gathering signatures to place the measure on the 2026 ballot.

To qualify for the ballot, Kind Idaho needs to collect around 70,000 signatures from registered Idaho voters. This includes gathering support from at least 6% of voters across at least 18 of the state’s thirty-five legislative districts. The group has until April 2026 to submit these petitions for the proposal to be officially added to the ballot.

The decision to push for a more limited legalization measure in Idaho aligns with recent trends in cannabis legislation, particularly following the failure of broader legalization efforts in other states. In the 2024 election, similar ballot measures in North Dakota and Florida were rejected by voters. South Dakota also saw a failed attempt to legalize cannabis possession without authorizing commercial sales.

As the legalization movement spreads to more states across the U.S. and reforms are enacted, numerous business opportunities are likely to be opened up, such as those that take their inspiration from the operations of entities like Innovative Industrial Properties Inc. (NYSE: IIPR).

Innovative Industrial Properties Inc. (IIPR), closed Tuesday's trading session at $106.2, up 1.3842%, on 227,832 volume. The average volume for the last 3 months is 3.838M and the stock's 52-week low/high is $77.88/$138.35.

C3.ai Inc. (AI)

Schaeffer's, InvestorPlace, Marketbeat, The Online Investor, INO Market Report, MarketClub Analysis, Early Bird, QualityStocks, Marketbeat.com, StreetInsider, Zacks, Investopedia, The Street, The Wealth Report, InvestorsUnderground, StockReport Newsletter, The Motley Fool, Smart Investing Society, FreeRealTime, Prince Report, Luke Lango, DividendStocks, TheStreet Daily, Chaikin PowerFeed, Energy and Capital, Financial Newsletter, Daily Trade Alert, Wealth Daily, InsiderTrades, CNBC Breaking News, Street Insider, 360 Wall Street, The Street Report, Contrarian Outlook, 52Patterns, Bernie Schaeffer, BioPharm International, MarketMovingTrends, Member Alerts, Zacks Weekend Wisdom, Mark Soberman, Marina 'The Trader Chick', Andrew Keene, LCGC, Lance Ippolito, Jeff Bishop, DailyMarketAlerts, Decentral Publishing, Investment House, Investing Breakout, Money Wealth Matters, Don Kaufman, Member Solutions, Future Trends Digest, Fierce Analyst, Josh Belanger, SE Stock Alert, TheoTrade, TipRanks, Norman Hallett, The Stansberry Digest, The Dividend Guy, Spectroscopy Webcasts, TradersPledge, StockReport, StrategicTechInvestor, Matt, Pharmaceutical Technology Webcasts, Trading Pub, Trading with Manny, Uptick Daily, Total Wealth, Eric Fry, Harry from Eltoro Market Insight, Summa Money, The Early Bird, Tim Sykes, Earnings360 Newsletter, Eagle Financial Publications, Dividend Report, Trade Out Loud, Daily Options Signals, Trades Of The Day, TradeSmith Daily, Cabot Wealth, AllPennyStocks, Top Pros Top Picks, StockEarnings Partner, Market Target, SE Trade Alert, Inside Trading, Stock Trading Partner, Premium Stock Alerts, Outsider Club, SmartMoneyTrading, StockEarnings, Stock Gumshoe, Jea Yu, InvestorPlace Digest, Investment News Daily, Investment Insights Report, StreetAuthority Daily, Money and Markets, OilAndEnergyInvestor, Wall St. Warrior, 247 Market News, Wall Street Greek, Prism MarketView, TradersPro, MicrocapAlliance, Stansberry Research, Dividend Opportunities, Liberty Through Wealth, Investiv, Timothy Sykes, Earnings360, Kiplinger Today, Tim Bohen, StockMarketWatch, The Night Owl, Investors Alley, Hit and Run Candle Sticks and Louis Navellier reported earlier on C3.ai Inc. (AI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

A new technique developed by mechanical and environmental engineering professor Markus J. Buehler will allow us to use artificial intelligence to predict how innovation will occur in the future.

Prof. Buehler of MIT explains that by combining graph-based computational tools with generative artificial intelligence, one can generate entirely new designs, concepts, and ideas. This, he notes, can be used to speed up scientific discovery by teaching generative artificial intelligence how to make new forecasts about unimaginable designs, concepts and ideas.

For his research, Buehler used graphs developed using techniques inspired by category theory to teach his model to understand associations in science.

Category theory is a mathematics branch that handles abstract structures and associations between them. It offers a framework for unifying and understanding different systems by focusing on objects and how they interact with other things. The artificial intelligence model was designed to uncover shared patterns of order and complexity.

In his research, the model discovered unanticipated similarities between Symphony No.9 by Beethoven and biological materials, proposing that both followed patterns of complexity. Through this approach, Buehler taught the model to methodically reason over different scientific behaviors and concepts.

In total, he analyzed one thousand scientific papers on biological materials and from the model, produced a graph which showed how different data was connected. The graph also showed groups of linked ideas and the points that linked different concepts.

Buehler explained that the graph followed a highly connected and scale-free nature which could be used for graph reasoning. He added that investigators could use the model to connect concepts that had never been linked before, suggest new material designs, answer difficult questions, find gaps in knowledge, and forecast how materials may behave.

For instance, the model could be used to develop biodegradable plastic alternatives, and innovative sustainable construction materials. In a separate experiment, the model recommended the creation of a new biological material based on the abstract patterns in Composition VII by Wassily Kandinsky.

With this advanced artificial intelligence model, researchers can draw insights from technology, art, and music to point out hidden patterns that could open up new possibilities for visual art, music, and material design.

Irving Langmuir Distinguished Professor of Chemical Sciences and Engineering, Nicholas Kotov, explained that graphs from Buehler’s work could be used as data maps that allowed researchers to identify new links, main topics, and possible research directions by exploring associations across subsections of biomimetic and bioinspired materials. Kotov was not involved in this study.

Buehler’s research was published in Machine Learning: Science and Technology.

As more AI innovations are brought to market by entities like C3.ai Inc. (NYSE: AI), a lot more use cases for this technology are likely to be uncovered leveraging the pattern recognition powers that Buehler’s study highlights.

C3.ai Inc. (AI), closed Tuesday's trading session at $32.96, up 24.1899%, on 27,941,881 volume. The average volume for the last 3 months is 42.684M and the stock's 52-week low/high is $18.85/$38.30.

Marathon Digital Holdings (MARA)

MarketClub Analysis, Schaeffer's, InvestorPlace, QualityStocks, INO Market Report, StockMarketWatch, StockEarnings, MarketBeat, StocksEarning, TradersPro, Early Bird, Zacks, Investors Underground, InvestorsUnderground, BUYINS.NET, The Online Investor, Lebed.biz, Premium Stock Alerts, Trades Of The Day, FreeRealTime, The Street, TraderPower, Marketbeat.com, Daily Trade Alert, 360 Wall Street, DailyMarketAlerts, BillionDollarClub, PoliticsAndMyPortfolio, CryptoCurrencyWire, TopPennyStockMovers, Wall Street Mover, Kiplinger Today, FeedBlitz, Wealth Insider Alert, Investment House, The Wealth Report, StreetAuthority Daily, MarketClub Options, Eagle Financial Publications, DreamTeamNetwork, Trading Pub, TradingPub, Wealth Daily, Barchart, AllPennyStocks, DividendStocks, Inside Trading, Promotion Stock Secrets, Investment News Daily, Street Insider, StockOodles, Jeff Bishop, Lance Ippolito, Stock Beast, Stock Analyzer, Rick Saddler, RedChip, ProsperityPub and StreetInsider reported earlier on Marathon Digital Holdings (MARA), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Marathon Digital Holdings (NASDAQ: MARA), a leading cryptocurrency mining company, is turning heads with its efficiency gains and strategic growth. H.C. Wainwright, a prominent research firm, has raised its price target for Marathon from $27 to $28 while maintaining its “Buy” rating. The upgrade acknowledges the company’s significant operational improvements and proactive strategies, demonstrating resilience and adaptability despite facing revenue challenges.

In its third-quarter earnings report for 2024, Marathon posted revenue of $131.6 million, reflecting a 9% decline from the previous quarter’s $145.1 million. Despite this dip, the company delivered remarkable operational results. Marathon’s energized hash rate, a key measure of mining power, surged by 17%, rising from 31.5 Eh/s to 36.9 Eh/s. By October, the operational hash rate had already hit 40.2 Eh/s, setting the stage for the company to achieve its ambitious year-end target of 50 Eh/s.

These gains are bolstered by cost efficiency improvements. MARA reduced its cost per petahash per day by 10%, bringing it down to $37.1 in Q3 from $41.0 in Q2. The cost-cutting success stems from the company’s transition to self-owned and operated mining sites which allows for better control and scalability.

But, Marathon’s goal is more than being efficient; it’s also making strides in sustainability. The Fort Lauderdale headquartered company has embraced innovative energy solutions, such as converting flared gas into power for its micro data centers. These near-zero-cost energy sources significantly reduce operational expenses while showcasing Marathon’s commitment to eco-friendly practices. The approach is a standout in the energy-demanding cryptocurrency mining sector, showing beyond doubt that the company is a leader in sustainability.

Besides, MARA recently acquired 372 megawatts (MW) of capacity across three sites in Ohio, increasing its total capacity to nearly 1.5 gigawatts (GW). The expansion proves that Marathon has what it takes to meet the growing demands of the cryptocurrency market.

Financially, Marathon is leveraging its hybrid strategy of buying and mining Bitcoin. With nearly 27,000 Bitcoin in its holdings valued at $2.5 billion, the company is maintaining financial flexibility while maximizing returns. This dual approach ensures stability even in the volatile crypto market.

Marathon’s performance highlights its broader achievements and steady progress over the past years. Energized hash rates surged by 93%, while revenues grew by 35%. The company’s decision to focus on scaling operations, reducing costs, and integrating innovative technologies positions it as a market leader in the cryptocurrency mining space.

For investors, the combination of strong operational performance, sustainability efforts, and strategic expansion by MARA creates a compelling growth story. H.C. Wainwright’s raised price target emphasizes the firm’s confidence in Marathon’s long-term potential. The company’s ability to adapt and innovate ensures it remains a key player in an increasingly competitive landscape.

With sustainability, efficiency, and growth at its core, Marathon is setting a direction towards more success in the world of cryptocurrency.

Marathon Digital Holdings (MARA), closed Tuesday's trading session at $19.86, up 9.6935%, on 88,677,438 volume. The average volume for the last 3 months is 798,312 and the stock's 52-week low/high is $9.88/$34.09.

VinFast Auto Ltd. (VFS)

QualityStocks, StockEarnings, Schaeffer's, Early Bird, MarketBeat, GreenCarStocks and InvestorPlace reported earlier on VinFast Auto Ltd. (VFS), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

President-elect Donald Trump’s second administration will likely see battery electric vehicle prices rise across the majority of the U.S. automotive market, sparing only Tesla thanks to its position in the market. Elon Musk’s decision to endorse his sophomore presidential bid was controversial; the former President has repeatedly criticized the Biden administration’s efforts to electrify the country’s transport sector and promised to get rid of the federal EV subsidies if elected.

Even though Trump toned down his anti-electric vehicle rhetoric after Musk’s endorsement, he is still set to eliminate the $7,500 federal tax credit for EV purchases that has facilitated a significant portion of the country’s electric vehicle sales. Musk noted in a statement posted on X that such a move could benefit Tesla by making it difficult for legacy automakers to introduce new electric cars to the market and compete with the Texas-based EV maker.

While Musk says he supports eliminating the tax credit, the vast majority of the American auto industry is vehemently opposed to the idea. An October letter from the Alliance for Automotive Innovation stressed that the tax credit shouldn’t be eliminated as it allows American carmakers to compete with Chinese automakers on a somewhat even footing.

Beijing has provided billions of dollars in subsidies to its auto sector over the past decade and continues to support the industry with massive subsidies. As a result, Chinese firms like BYD can mass produce electric cars at relatively low prices, allowing them to sell their EVs at much lower prices compared to their Western counterparts.

As electric cars are still more expensive compared to similar internal combustion engine (ICE) cars by a notable margin, federal subsidies and incentives have been key to boosting electric vehicle sales in the U.S. for the past decade. Even with subsidies, most carmakers in the West are selling electric cars at a loss, leaving Tesla as the only automaker in the U.S. profiting from electric vehicle sales.

If Trump gets rid of the $7,500 tax incentive, automakers would have to either make even greater losses to keep their EV divisions running or reduce their investment in electric cars. The Zero Emission Transportation Association (ZETA) is urging President-elect Donald Trump to consider retaining the incentive as it has also created employment opportunities in Republican-leaning states such as Georgia, Kentucky, Michigan, and Ohio.

Edmund analysts also note that losing the incentive without some form of replacement could jeopardize electric vehicle sales in the U.S. It would be interesting to see how the anticipated policy changes in the U.S. could impact foreign EV makers like VinFast Auto Ltd. (NASDAQ: VFS) that are eyeing the U.S. market.

VinFast Auto Ltd. (VFS), closed Tuesday's trading session at $4.05, up 1.25%, on 851,904 volume. The average volume for the last 3 months is 8.128M and the stock's 52-week low/high is $2.255/$9.30.

Quantum Computing Inc. (QUBT)

QualityStocks, InvestorPlace, MarketClub Analysis, TradersPro, Premium Stock Alerts and BUYINS.NET reported earlier on Quantum Computing Inc. (QUBT), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Quantum (NASDAQ: QUBT) ("QCi"), an innovative, integrated photonics and quantum optics technology company, recently announced its entry into a securities purchase agreement for the purchase and sale of 16,000,000 shares of common stock, each at a purchase price of $2.50, priced at-the-market under Nasdaq rules, pursuant to a registered direct offering. Of the expected gross proceeds to QCI of $40 million, the company intends to use the net for the repayment of debt, working capital and general corporate purposes. Titan Partners Group, a division of American Capital Partners is acting as the sole placement agent for the offering.

To view the full press release, visit https://ibn.fm/alONo

About Quantum Computing Inc. (“QCi”)

“QCi” is an innovative, integrated photonics and quantum optics technology company that provides accessible and affordable quantum machines to the world today. The company’s products are designed to operate at room temperature and low power at an affordable cost. QCi's portfolio of core technology and products offer distinctive capabilities in the areas of high-performance computing, artificial intelligence, cybersecurity, as well as remote sensing applications.

Quantum Computing Inc. (QUBT), closed Tuesday's trading session at $2.54, up 6.2762%, on 25,364,166 volume. The average volume for the last 3 months is 7.464M and the stock's 52-week low/high is $0.3549/$4.69.

Canaan Inc. (CAN)

QualityStocks, MarketClub Analysis, Schaeffer's, StockEarnings, InvestorPlace, TradersPro, MarketBeat, CryptoCurrencyWire, AllPennyStocks, StreetInsider, Stockhouse, Dividend Report, Energy and Capital, INO Market Report, Investment Insights Report, Investors Alley, Acorn Wealth, Wealth Daily, The Online Investor, InvestorsUnderground, SmarTrend Newsletters, Stock Fortune Teller, StockMarketWatch, StocksEarning, Early Bird, The Street, BUYINS.NET, TopStockAnalysts and Trades Of The Day reported earlier on Canaan Inc. (CAN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

A hacker tied to one of the biggest crypto thefts in history has been given a five-year sentence in a United States jail for money laundering. Ilya Lichtenstein admitted his guilt last year in a case involving the 2016 hacking of the Bitfinex exchange which resulted in the theft of almost 120,000 bitcoins.

Lichtenstein conducted the laundering operation with Heather Morgan, his wife, better known by her rap name “Razzlekhan.” Back then, the stolen Bitcoin was worth approximately $70 million. However, by the time authorities apprehended the couple, the value of the cryptocurrency had skyrocketed to over $4.5 billion. Today, the bitcoin would be worth more than double that amount.

The case led to the biggest financial asset recovery in the history of the DOJ with $3.6bn seized. Lisa Monaco, the U.S. Deputy Attorney General, referred to it as a record-breaking moment for law enforcement at the time. Judge Colleen Kollar-Kotelly emphasized the significance of holding criminals accountable, stating, “These crimes carry consequences.”

Lichtenstein is still in custody since February 2022 when he was arrested. He voiced remorse for his deeds during his hearing and shared his intention to deploy his cybersecurity skills to help combat cybercrime once he has served his time.

Heather Morgan also entered a guilty plea last year to a single charge of conspiracy to commit money laundering. Her sentencing is scheduled for November 18.

Court records revealed that Lichtenstein used advanced hacking methods to break into Bitfinex’s systems and steal the Bitcoin. Afterward, he turned to Morgan to help him disguise and move the stolen crypto.

According to a DOJ statement, the duo employed a variety of sophisticated money-laundering tactics. These included creating fake identities, converting the stolen funds into different cryptos, and purchasing golden coins. Prosecutors additionally noted that Lichtenstein often travelled with family to meet couriers and transfer the laundered proceeds to his home country—Russia.

Morgan gained widespread attention online when the case became public, thanks to her persona “Razzlekan.” She released numerous rap songs and music videos filled with explicit lyrics, often shot at locations across New York City even as the two tried to cover their tracks. She described herself in her lyrics as Wall Street’s crocodile and a “bad-ass money maker.”

According to Forbes magazine articles, Morgan further described herself as a rapper, software investor, economist, and serial entrepreneur.

Cases of crypto theft like these ones could be nudging blockchain equipment manufacturers like Canaan Inc. (NASDAQ: CAN) to add functionalities to their chips so that security measures can be enhanced by their clients who are wary of falling prey to hackers.

Canaan Inc. (CAN), closed Tuesday's trading session at $1.59, up 3.9216%, on 11,045,212 volume. The average volume for the last 3 months is 292,168 and the stock's 52-week low/high is $0.72/$3.50.

TerrAscend Corp. (TSNDF)

QualityStocks, CannabisNewsWire, InvestorPlace and Cabot Wealth reported earlier on TerrAscend Corp. (TSNDF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

A few months ago, the Department of Cannabis Control in the state of California issued 5 cannabis product recalls. The recalls drew attention to the presence of aspergillus, which brought the total number of recalls to twenty-one for the year.

The significant increase in recalls related to mold, in particular aspergillus, has made marijuana cultivators across the state to become more vigilant.

So, what do we know about aspergillus?

This mold can be found in decaying vegetation, soil and the air. It thrives in humid and warm environments, with its spores possessing the ability to travel long distances. This makes it hard to contain the mold in outdoor or even indoor cultivation operations.

While most strains of aspergillus are harmless, specific species can cause serious respiratory issues for individuals with underlying lung conditions, asthma, or weak immune systems. Other species can also cause infections, ranging from invasive aspergillosis to mild allergies.

Given that medical marijuana is used by patients with compromised immune systems, it is even more important to ensure that the products consumers have access to are mold-free.

What happens when a product fails a laboratory test?

States often carry out compulsory lab tests on marijuana products sold in their jurisdictions. Products that don’t pass these tests due to high mold levels are often turned into extracts or remediated, which decreases a cultivator’s profit margins.

For instance, the Metrc’s marijuana track-and-trace system in Florida usually flags remediated flower and labels it with an R. This negatively impacts the product’s market appeal and causes a decline in the average price of the product over time.

This approach isn’t sustainable for cannabis cultivators who’re trying to maintain profitability and a competitive edge.

How can marijuana decontamination help prevent this from happening?

Introducing a decontamination step in one’s cultivation process can substantially decrease the presence of mold before cannabis products are submitted for lab tests. The primary objective of this step is to reduce the levels of microbials present in the cannabis flower, normally through a sterilization or sanitization process.

By integrating this safeguard into one’s procedures, growers can avoid the reputational and financial damage associated with product recalls and failed laboratory tests.

What decontamination solutions can cultivators use?

  1. Ozone gas is known to decrease microbial levels on plants, including marijuana.
  2. X-ray radiation, which can help deactivate the DNA of harmful pathogens.
  • Radio frequency treatment can also help eliminate pathogens.

One should keep in mind that these solutions don’t compromise the quality of the cannabis flower.

For companies like TerrAscend Corp. (TSX: TSND) (OTCQX: TSNDF) that have worked to build their reputation within the industry, every effort would be worthwhile if it helped to avoid harming what they have so far achieved.

TerrAscend Corp. (TSNDF), closed Tuesday's trading session at $0.83, off by 9.4875%, on 134,937 volume. The average volume for the last 3 months is 5.952M and the stock's 52-week low/high is $0.66/$2.45.

The QualityStocks Company Corner

D-Wave Quantum Inc. (NYSE: QBTS)

The QualityStocks Daily Newsletter would like to spotlight D-Wave Quantum Inc. (NYSE: QBTS).

The successful calibration and benchmarking of the 4,400+ qubits Advantage2 processor is a significant milestone in D-Wave's ongoing development of its sixth-generation annealing quantum computing system.

Advantage2 has significantly more computational power than the current Advantage(TM) system, able to solve certain customer problems 25,000 times faster.

Advantage2 offers improvements in areas such as faster time-to-solution, higher quality solutions, and ability to solve larger problems.

D-Wave (NYSE: QBTS), a leader in quantum computing systems, software and services, and the first commercial provider of quantum computers, has achieved a significant milestone in the ongoing development of its sixth-generation annealing quantum computing system by completing the calibration and benchmarking of a 4,400+ qubit Advantage2 processor (https://ibn.fm/SEoTd).

D-Wave Quantum Inc. (NYSE: QBTS) is a leader in quantum computing systems, software and services focused on delivering customer value via practical quantum applications for problems such as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, fault detection and financial modeling. As the only provider building both annealing and gate-model quantum computers, the company is unlocking commercial use cases in optimization today, while building the technologies that will enable new solutions tomorrow.

D-Wave is a pioneer in quantum computing, with a history of delivering the world’s first commercial quantum computer; the first real-time quantum cloud service; countless hardware and software product and research milestones; and the planned first cross-platform quantum solution which will deliver both annealing and gate-model quantum computers to customers via an integrated platform. Its current commercial product offerings include: Advantage™ (fifth generation quantum computer), Leap™ (quantum cloud service), Launch™ (quantum computing onboarding service) and Ocean™ (full suite of open-source programming tools).

D-Wave’s relentless pursuit of practical quantum computing has resulted in the technology being used today by some of the world’s most advanced enterprises – more than 25 of the Forbes Global 2000 use D-Wave.

D-Wave’s commercial customers include blue-chip industry leaders like Volkswagen, Accenture, BBVA, NEC Corporation, Save-On-Foods, DENSO and Lockheed Martin. The company boasts an extensive IP portfolio featuring more than 200 issued U.S. patents and over 100 peer-reviewed papers published in leading scientific journals.

Founded in 1999, D-Wave is the world’s first commercial supplier of quantum computers. With headquarters and the Quantum Engineering Center of Excellence based near Vancouver, Canada, D-Wave’s U.S. operations are based in Palo Alto, California.

Advantage™ Quantum Computer

 

With the Advantage™ Quantum Computer, D-Wave has incorporated two decades of experience and over 10 years of customer feedback to create the first and only quantum computer designed for business. The platform features a new processor architecture with over 5,000 qubits and 15-way qubit connectivity. This is 2.5x more connections and more than double the number of qubits than the company’s previous generation quantum computer.

D-Wave’s quantum computers, first located in its facilities in British Columbia, have been available to North American users through its Leap™ quantum cloud service since 2018. It has since introduced new Advantage systems in Julich, Germany, and most recently, Marina Del Rey, California, which marked the availability of the first Advantage quantum computer physically located in the United States.

That new deployment is part of the USC-Lockheed Martin Quantum Computing Center (QCC) hosted at USC’s Information Sciences Institute (ISI), a unit of the University of Southern California’s prestigious Viterbi School of Engineering. Additionally, Amazon Web Services (AWS) and D-Wave announced that the U.S.-based system is available for use in Amazon 2racket, expanding the number to three different D-Wave quantum systems available to AWS users.

Leap Quantum Cloud Service

 

D-Wave’s customers interface with its systems through the Leap™ quantum cloud service. Leap delivers immediate, real-time access to the company’s Advantage quantum computer and quantum hybrid solver service, all with enterprise-class performance and scalability.

Leap allows developers proficient in Python to get started building and running quantum applications. Through a seamless and secure cloud-based connection, users can easily start solving complex problems of up to 1 million variables and 100,000 constraints.

Using Leap, D-Wave customers have developed quantum hybrid applications for use cases in manufacturing, logistics, financial services, life sciences, materials science, retail and transportation. By eliminating the need to wait hours, days or weeks to get good answers to a broad array of problems, D-Wave is helping businesses move forward.

D-Wave Launch

D-Wave Launch™ is the company’s onboarding platform aimed at helping businesses easily start their quantum journey. Through this program, D-Wave’s team of experts and partners aid enterprises in identifying best use cases for quantum and work with them to develop a proof of concept and production pilot.

From there, the team coordinates with customers to get their hybrid quantum applications up and running, providing ongoing Leap quantum cloud access to ensure the application is operating smoothly and delivering real business value.

Target Verticals

While the potential applications for quantum computing are effectively limitless, D-Wave has identified a number of industry verticals as key areas of focus for its quantum architecture, providing case studies for each. These include:

  • Manufacturing – D-Wave worked with Volkswagen to identify a commercial optimization application, the binary paint shop problem, which was run on D-Wave’s hybrid solver service. The solver outperformed four purely classical methods on problem sizes at commercial scale (N=3,000). In a separate project, similar inputs were tested using a leading ion trap system, which failed to find any commercial solution.
  • Life Sciences – Menten AI makes use of D-Wave quantum computing to assist in the design of novel therapeutic peptides—short strings of amino acids that can act as potent drugs. With the rise of COVID-19, D-Wave’s Advantage system made it possible to identify molecules that might be especially well-suited for binding and inhibiting the related spike protein, producing several promising peptide designs.
  • Finance – Multiverse Computing, a leader in developing quantum solutions for the financial sector, leveraged D-Wave’s hybrid solver service in a collaboration with BBVA, one of the world’s largest financial institutions. Multiverse demonstrated management strategies that far exceeded the granularity of traditional returns in a fraction of the time, helping BBVA identify a low-risk portfolio for investment.

Market Opportunity

The quantum computing total addressable market is projected to grow between $450 billion and $850 billion over the next 15 to 30 years, with between $5 billion and $10 billion of anticipated TAM growth coming in the next three to five years, according to Boston Consulting Group. Driving factors behind this growth include rising investments in quantum computing tech by governments and an increasing number of commercial use-cases.

Forward-thinking organizations see quantum as an opportunity to move ahead of the competition. From finding efficiencies and reducing waste to decreasing time to solution and solving problems abandoned due to complexity, the business value is real. According to data from 451 Research, 40% of large enterprises are already experimenting with quantum computing.

D-Wave is strategically positioned – in an industry with significant barriers to entry – as evident by a decades-long track record serving a roster of blue-chip customers. The company is singularly focused on helping its customers achieve clear value by leveraging quantum computing in practical business applications. With a full stack of systems, software, developer tools and services, D-Wave is working to enable enterprises, governments, developers and researchers to access the power of quantum computing, thereby providing an intriguing opportunity for prospective investors.

D-Wave’s current investor base includes PSP Investments, Goldman Sachs, BDC Capital, NEC Corporation, Aegis Group Partners and In-Q-Tel.

Leadership Team

Dr. Alan Baratz has served as the CEO of D-Wave since 2020. Previously, as Executive Vice President of R&D and Chief Product Officer, he drove the development, delivery, and support of all of D-Wave’s products, technologies, and applications. Dr. Baratz has over 25 years of experience in product development and bringing new products to market at leading technology companies and software startups. As the first president of JavaSoft at Sun Microsystems, he oversaw the growth and adoption of the Java platform from its infancy to a robust platform supporting mission-critical applications in nearly 80 percent of Fortune 1000 companies. He has also held executive positions at Symphony, Avaya, Cisco, and IBM. Dr. Baratz holds a doctorate in computer science from the Massachusetts Institute of Technology.

John Markovich is the company’s CFO. He brings to D-Wave over three decades of experience working with rapidly growing private and public technology companies across all stages of development. Mr. Markovich has directed the finance, accounting, tax, treasury, M&A, legal, operations, customer service, IR, HR, and IT functions for companies ranging from privately held pre-revenue startups to an NYSE-listed Fortune 500 multi-national company with over $1.2 billion in annual revenue. During his career, he has negotiated and closed over 150 debt, equity, M&A, and joint venture transactions exceeding $2.5 billion in value; over a dozen private placements; nearly a dozen M&A transactions; and several international joint ventures. Mr. Markovich holds a BS in Business from Miami University and an MBA from the Michigan State Graduate School of Business.

D-Wave Quantum Inc. (NYSE: QBTS), closed Tuesday's trading session at $1.49, up 3.4722%, on 11,297,747 volume. The average volume for the last 3 months is 76,565 and the stock's 52-week low/high is $0.6813/$2.44.

Recent News

HeartBeam Inc. (NASDAQ: BEAT)

The QualityStocks Daily Newsletter would like to spotlight HeartBeam Inc. (NASDAQ: BEAT) .

HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights wherever the patient is, today announced the results from two studies evaluating its groundbreaking vector-based technology. According to the announcement, the data add to the body of evidence for HeartBeam's key clinical indications, specifically arrhythmia and heart attack (myocardial infarction) detection, and showcase the technology's pivotal role in advancing patient care. The studies were presented during the American Heart Association's annual Scientific Sessions in Chicago, Nov. 16-18, 2024.

"The data presentations at AHA are a testament to HeartBeam's dedication to building a robust body of clinical evidence to support our groundbreaking technology as we strive to make it easier for patients and physicians to monitor cardiac symptoms and seek timely diagnosis outside of a healthcare facility," said HeartBeam CEO Robert Eno. "We thank our physician collaborators for their commitment to evaluating the value our technology can bring in different clinical situations and transform how cardiac conditions are managed in the future."

To view the full press release, visit https://ibn.fm/DVvqX

HeartBeam Inc. (NASDAQ: BEAT) is a cardiac technology company that has developed the first and only 3D-vector 12-lead electrocardiogram (ECG) platform for heart attack detection anytime, anywhere. The company’s proprietary ECG telehealth technology aims to redefine the way high risk cardiovascular patients are diagnosed in ambulatory and acute care settings. HeartBeam’s initial focus is on providing diagnostic data to help physicians with care management of patients with cardiovascular disease.

In August 2022, HeartBeam announced that it submitted its HeartBeam AIMI™ software for approval from the U.S. Food and Drug Administration (FDA). HeartBeam AIMI is a platform technology to improve the speed and accuracy of heart attack detection in acute care settings. The company expects FDA approval by the end of 2022, and a full commercial roll-out of HeartBeam AIMI is targeted for Q1 2023.

HeartBeam sees submission of its first product based on its platform technology as an important milestone toward commercialization, which underscores the company’s continued progress toward making the HeartBeam AIMI platform widely available to help emergency department physicians quickly and accurately identify a heart attack.

While the FDA conducts its regulatory review, HeartBeam will focus on executing key components of its commercialization plan and subscription revenue model. It will also continue to engage in discussions with strategic institutions, including academic centers, regional healthcare systems and regional community hospital systems that can utilize HeartBeam products.

The company is based in Santa Clara, California.

Products

HeartBeam’s development portfolio includes two products:

  • HeartBeam AIMI is software that provides a 3D comparison of baseline and symptomatic 12-lead ECG to more accurately identify a heart attack in acute care settings and, as noted above, has been submitted for FDA approval; and
  • HeartBeam AIMIGo™, the first and only credit card-sized 12-lead output ECG device coupled with a smartphone app and cloud-based diagnostic software system for remote heart attack detection.

HeartBeam is developing AIMIGo, a medical-grade detection and monitoring technology for use in remote heart attack detection, thereby allowing physicians to diagnose a patient’s heart attack as it occurs, even if the patient is not at a medical facility. The company’s system, once approved by the FDA, can be used by patients at home or almost anywhere and anytime to help their physicians assess whether chest pain is the result of a heart attack or another cause. While approximately 82% of chest pain ED visits are unnecessary, patients delay approximately 3 to 4 hours after symptoms begin, increasing mortality rates by 40%. The company’s goal is to shorten the time to treatment outside of the medical facility to improve patients’ well-being.

HeartBeam’s AIMIGo is a powerful, portable and easy-to-use prescription-based product. It comprises a smartphone app, a credit card-sized ECG device placed on a patient’s chest, the HeartBeam cloud platform, and a digital portal for the physician to view ECG results and direct patient action. For the first time outside of a medical setting, HeartBeam AIMIGo enables patients and their clinicians to determine if symptoms are due to a heart attack, quickly and easily, so care can be expedited, if needed.

Pending FDA clearance, AIMIGo is initially intended to be available by prescription, and is reimbursable under existing remote patient monitoring codes (RPM codes). This provides a new revenue stream to physicians who before did not have a way to monitor these high-risk patients. The RPM codes provide a monthly reoccurring revenue stream to the company, as well. On average, at current reimbursement rates, the practice will receive $1,300+ per year per patient they monitor, and the company will receive $600 per year per patient from this RPM reimbursement.

Market Overview

Adoption rates of telehealth services increased dramatically in recent years, with the COVID-19 pandemic serving as a major driver of growth. Among the areas seeing the greatest expansion are cardiology, radiology, behavioral health and online consultation.

Encouraging this growth, governments are actively developing new policies and reimbursement guidelines to promote the use of digital health platforms. The U.S. Centers for Medicare & Medicaid Services (CMS), for example, has recently expanded reimbursement for telehealth services. U.S. market growth is also being driven by the rising prevalence of chronic conditions and the growing geriatric population.

Remote heart attack detection is a previously unsolved problem with a massive and underserved market that is several times larger than the $2 billion total addressable market (TAM) in the U.S. for ECG cardiac arrhythmia monitoring.

Approximately 8 million Americans have suffered at least one heart attack, and a total of 18 million have been diagnosed with coronary artery disease (CAD). Based on these figures, HeartBeam projects a total addressable U.S. market TAM valued at $10 billion annually for its AIMIGo solution for remote heart attack monitoring of CAD.

Management Team

Branislav Vajdic, Ph.D., Chief Executive Officer and Founder of HeartBeam, Inc, combines over 30 years of experience in technology development and senior management positions. Dr. Vajdic has been deeply involved with the development of HeartBeam’s technology to fit his vision for the company. Prior to HeartBeam, from 2007 to 2010, Dr. Vajdic was CEO and Founder of NewCardio, a publicly traded company in the cardiovascular devices space. From 1984 to 2007, Dr. Vajdic was at Intel, where he held various senior management position. At Intel, Dr. Vajdic was the designer of first Flash memory and two key inventions that enabled Flash as a product and led engineering groups responsible for Pentium 1 through Pentium 4 designs. Dr. Vajdic was awarded two Intel Achievement Awards, the highest level of award for outstanding contributions to Intel. Dr. Vajdic is author of numerous patents and publications in the fields of cardiovascular devices, as well as chip design. Dr. Vajdic holds a Ph.D. in Electrical Engineering from the University of Minnesota.

Jon Hunt, Ph.D., has over 35 years’ experience in the medical/medical device industry with extensive domestic and international experience in general management, clinical/regulatory, sales and marketing. He also has diverse experience in Fortune 500 companies, as well as start-up environments. Dr. Hunt was the Vice President of Clinical Science and Technology, Medical Device Innovation Consortium, from July 2019 to July 2021, and Vice President of Clinical and Regulatory Affairs, Cryterion Medical from January 2018 to June 2019 (acquired by Boston Scientific Corporation in July 2018 for $202M). Dr. Hunt was the Founding President and CEO of Bardy Diagnostics, Inc. from October 2013 to November 2017 (acquired by Hill-Rom Holdings, Inc.). Prior to joining Bardy Diagnostics, Dr. Hunt spent the previous 11 years as the Vice President of Clinical & Regulatory Affairs with Cameron Health, Inc. (acquired by Boston Scientific Corporation). Dr. Hunt spent the previous 10 years with Cardiac Pacemakers, Inc., St. Jude Medical and Cardiac Pathways Corporation. Dr. Hunt began his career with Cardiac Pacemakers, Inc. (now Boston Scientific Corporation) as the Director of Clinical Programs. He subsequently held positions at St. Jude Medical in Clinical Affairs and as the Business Unit Director for the Cardiac Rhythm Management division for Europe, the Middle East and Africa. At Cardiac Pathways Corporation, Dr. Hunt held various executive positions as Vice President of International Sales and Marketing and Vice President of Worldwide Sales and Marketing (acquired by Boston Scientific Corporation). Dr. Hunt received his Ph.D. in Motor Control from The Pennsylvania State University, his Master’s from California State University, Long Beach and his undergraduate degree from Keele University in the United Kingdom.

Rick Brounstein, HeartBeam’s Chief Financial Officer, combines over 30 years of experience in health technology senior management. Since 2017, Mr. Brounstein has been and is currently a partner of Hardesty, LLC, a financial services firm, and Mr. Brounstein is currently a managing director of CTRLCFO, LLC, a firm Mr. Brounstein founded in 2016 to support funded start-ups in life science and technology. From 2008 to 2011, Mr. Brounstein was Chief Financial Officer of NewCardio, Inc., a microcap public company in the cardiology space, and, over his career, he has been with nine other companies in life science or technology, holding positions including Chief Financial Officer, Chief Operating Officer, Treasurer and Accounting Manager. From June 2001 through November 2007, Mr. Brounstein held several positions at Calypte Biomedical Corporation, a publicly traded medical device company, including Chief Financial Officer and Executive Vice President. In January 2007, Mr. Brounstein was appointed as the National Member Representative for the 2007 COSO Monitoring Project, which published new guidelines for monitoring internal financial controls in February 2009; Mr. Brounstein subsequently was a member of the FEI task force that issued the updated COSO Internal Control Framework in 2013. In March 2005, Mr. Brounstein was appointed to the SEC Advisory Committee on Smaller Public Companies. Mr. Brounstein earned his Certified Public Accountant (CPA) certification while working at Arthur Andersen LLP, formerly a public accounting firm. Mr. Brounstein holds a B.A. in accounting and an M.B.A. in finance, both from Michigan State University.

Ken Persen, HeartBeam’s Chief Technology Officer, combines over 28 years of experience in the medical device and digital health industries in engineering and senior management positions. Mr. Persen has been involved in several companies in Cardiac Rhythm Management, holding positions including Chief Executive Officer, Chief Technology Officer, Executive Vice President and Director of Engineering. Since 2016 and prior to joining HeartBeam, Mr. Persen was the Chief Technology Officer at LIVMOR, Inc., a digital health company. In addition, from 2016 through November 2021, he was also Chief Executive Officer of LIVMOR. Prior roles included Director of Engineering at Cameron Health (acquired by Boston Scientific), a late-stage medical device start up, and engineering and management positions at Guidant Corp. (acquired by Boston Scientific), a large medical device manufacturer. He has an undergraduate degree from University of Minnesota, Duluth, with a BA in Computer Science.

HeartBeam Inc. (NASDAQ: BEAT), closed Tuesday's trading session at $2.5, up 4.6025%, on 125,883 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $2.44/$.

Recent News

Nightfood Holdings Inc. (OTCQB: NGTF)

The QualityStocks Daily Newsletter would like to spotlight Nightfood Holdings Inc. (OTCQB: NGTF).

Nightfood Holdings (OTCQB: NGTF) subsidiary Future Hospitality Ventures Holdings Inc. ("FHV"), has announced an exclusive partnership with Bear Robotics Inc. to implement AI-driven service robots in the U.S. hospitality sector, starting in Greater Los Angeles with plans for nationwide expansion. FHV aims to address industry challenges like labor shortages and rising operational costs by introducing Bear Robotics' flagship "Servi" robots, which enhance efficiency and guest experiences in hotels, restaurants, and event spaces. This collaboration positions FHV to capture growth in the expanding hospitality robotics market, projected to exceed $3 billion by 2027, while inviting investors to participate in its transformative journey.

To view the full press release, visit https://ibn.fm/ya28H

Nightfood Holdings Inc. (OTCQB: NGTF) is a visionary holding company focused on identifying and capitalizing on explosive market trends within hospitality, food services and consumer packaged goods. By leading newly emerging categories and seizing opportunities in markets undergoing transformational upheaval, the company’s mission is to create unparalleled upside potential in industries ripe for innovation and growth.

Subsidiaries

Nightfood Inc.

The company’s flagship subsidiary, Nightfood Inc., is changing the way the world snacks at night. Humans are biologically hard-wired to crave sweets and fats at night – a survival mechanism from our hunter-gatherer days. Modern consumers know bingeing excess calories before the long nightly fast is no longer necessary for survival, but exploding screen time and decreased willpower at night results in over 90% of American adults snacking between dinner and bed every week, contributing to an estimated one billion nighttime snack occasions weekly (according to SleepFoundation.org).

The most popular choices – ice cream, cookies, chips and candy – are not only unhealthy but also impair sleep quality due to their nutritional profiles. Nightfood snacks are uniquely formulated by sleep and nutrition experts to satisfy nighttime cravings AND support better sleep.

Market Opportunity

Euromonitor International projects the American snack market will grow from $150 billion in 2022 to $170 billion in 2027. Snacking between dinner and bed is estimated to account for over $60 billion annually, creating an opportunity for a multi-billion-dollar sub-category to emerge in the coming years: sleep-friendly snacking.

Nightfood is the brand pioneering that category.

Nightfood’s innovation has led to partnership overtures from global giants, including the largest food and beverage company in the world, Nestlé, with whom Nightfood completed a “test-and-learn” joint initiative in 2023.

Management believes that successfully scaling Nightfood’s 2024 direct-to-consumer launch of sleep-friendly cookies will bring the category to life, opening the door for partnerships with and potential acquisition by global snack giants seeking to lead this potential billion-dollar emerging sub-category.

Future Hospitality Ventures Holdings Inc. (d/b/a roboOp365)

Future Hospitality Ventures Holdings, operating under the brand roboOp365, is revolutionizing the hospitality industry with cutting-edge automation and robotic solutions.

roboOp365 enhances operational efficiency and guest experiences through innovative technologies, including automated culinary bot, server robots and AI-enhanced applications. roboOp365 helps hospitality providers reduce costs, streamline operations and deliver superior service by integrating these advancements.

Market Opportunity

The robots-as-a-service (RaaS) business model has gained significant traction, super-charged by the COVID-19 pandemic, which instantly catalyzed game-changing growth and application. According to Verified Market Research, the service robotics market is projected to reach $173.17 billion by 2030, growing at a compound annual growth rate (CAGR) of 21.25%. Compared to Asia, the United States market is in the early stages of adopting these technologies, but acceptance is accelerating aggressively.

Several factors are driving this trend. Key industries such as hotels and restaurants are still struggling to rebound from the pandemic’s impact, hoping to return to pre-pandemic levels, if possible. Such recovery will largely be dependent upon service robots. In California specifically, factors such as rising labor costs, more rigorous labor laws and ongoing high turnover rates in labor-intensive sectors make it impossible for businesses to survive, thrive and compete without robotics.

Innovation Across Sectors

Nightfood Holdings Inc. is dedicated to driving innovation across its focus sectors of food services, automation and hospitality applications. In food services, the company leverages automation technology to drive operational efficiency for operators while meeting evolving consumer needs. In the hospitality industry, it’s deploying solutions that redefine guest experiences. Nightfood’s consumer-packaged goods initiatives are key to breakthrough trends in health and wellness.

Synergizing Food and Technology

The synergy of food and technology within Nightfood Holdings Inc. creates a holistic approach to innovation and automation. By integrating these areas, the company offers comprehensive solutions that address multiple facets of market needs. Its automation and artificial intelligence solutions in food service and hospitality create a seamless and enhanced consumer experience.

Through this integrated approach, Nightfood Holdings Inc. not only meets current market demands but also anticipates and influences future trends, positioning itself as a leader in innovation across these interconnected sectors. Synergies in these related and explosive categories result in operational efficiency and benefits for the company’s customers and partners and outsized upside and opportunity for its investors.

Management Team

Sean Folkson is the Chairman and President of Nightfood. He founded Nightfood when he couldn’t find a solution to his nighttime snacking problem. Recognizing the growing body of research linking nutritional intake with sleep quality, he launched the first snack brand specifically formulated to give consumers better, healthier and more sleep-friendly snacks for that peak-cravings slot between dinner and bed. He is a serial entrepreneur and problem-solver, having previously founded Specialty Equipment Direct, an online distributor of floor removal equipment, and AffiliatePros.com, a pioneering company in online affiliate marketing.

Lei Sonny Wang is the CEO of Nightfood Holdings. He is a strategist and business driver for early-stage and growth-stage companies. He is the founder and former CEO of Future Hospitality Ventures Holdings Inc., which was acquired by Nightfood Holdings Inc. At Future Hospitality, he leveraged his significant international business development experience into distribution relationships with leading global robotics manufacturers. At Nightfood, he is working to grow revenue and improve performance and profitability across all subsidiaries.

Nightfood Holdings Inc. (OTCQB: NGTF), closed Tuesday's trading session at $0.0121, up 5.2174%, on 197,230 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.0075/$0.035.

Recent News

Energy and Water Development Corp. (OTCQB: EAWD)

The QualityStocks Daily Newsletter would like to spotlightFathom Energy and Water Development Corp. (OTCQB: EAWD) .

With the 2030 deadline for doubling energy efficiency and tripling green energy capacity just a few years away, nations are deploying affordable wind and solar energy at record pace. The ongoing 2024 United Nations Climate Change Conference (COP29) in Baku, Azerbaijan has seen a series of announcements that could accelerate the global transition to renewables in time to meet green energy goals. For starters, the Utilities for Net Zero Alliance (UNEZA) announced that its membership has doubled since its launch at COP28. UNEZA was established under the guidance of the UN Climate Change High-Level Champions and the International Renewable Energy Agency (IRENA). The Breakthrough Agenda also launched the Hydrogen Action Declaration to solicit more political support for scaled-up hydrogen production, with Singapore and Kazakhstan as new signatories. Hydrogen could potentially supplement solar and wind which are intermittent in nature and can only produce energy efficiently in certain conditions. These efforts by governments and major organizations will complement what for-profit actors like Energy and Water Development Corp. (OTCQB: EAWD) are doing to bring innovations geared at boosting sustainability and clean energy use.

Energy and Water Development Corp. (OTCQB: EAWD) is a green-tech engineering solutions company focused on delivering water and energy to extreme environments. The company builds water and energy systems out of already existing, proven technologies, utilizing its patent-pending systems configuration and technical know-how to customize solutions to meet clients’ needs. To date, two water systems have been sold and deployed in Mexico and Germany, and the company is working to fulfill additional orders.

Using its patent-pending design, EAWD is working to build and operate off-grid EV charging stations in Germany. The company is a United Nations-accredited vendor and offers design, construction, maintenance and specialty consulting services to private companies, government entities and non-government organizations for the sustainable supply of energy and water.

EAWD focuses on three main aspects of the water and energy business: (1) generation, (2) supply and (3) maintenance. The green tech industry is constantly evolving due to ongoing and increasing water scarcity, as well as increased energy needs in the world. Therefore, the company believes that by designing sustainable and renewable solutions to these problems, EAWD will become an essential component of a rapidly growing industry with many new markets.

EAWD’s approach seeks to assist businesses with the growth and development of their general operations by ensuring the efficient, profitable and sustainable supply and generation of water and energy, allowing its potential customers to focus on their business while adopting strategies of sustainability.

By using the state-of-the-art technological solutions and technologies identified, designed and provided by EAWD and its collaborators, the company believes that its potential clients will be free to focus on the performance of their operations, as well as with the water and energy consumption or generation regulations within their industries.

EAWD is headquartered in Saint Petersburg, Florida, with operations in Germany and Mexico.

Products

In view of the increased worldwide demand for water and energy, EAWD’s business goals are focused on self-sufficient energy-supplied water generation and green energy production. To accomplish this, the company set out to establish an outsourcing green tech platform to commercialize its state-of-the-art technologies while providing engineering and technical consultation services to design the most sustainable technological solutions that can provide water and energy.

The company has sought potential collaboration with green tech research and development centers in Europe and has established its operating subsidiaries in Hamburg, Germany, where EAWD has started to assemble its patent-pending innovative off-grid, self-sufficient energy supply atmosphere water generation (AWG) systems.

EAWD Deutschland and EAWD Logistik operate in Hamburg, Germany, to meet the increasing demands of water and energy generation projects around the world, as well as to operate the solar-powered EAWD Off-Grid EV Charging Stations, EAWD’s newest product.

The company expects to offer sustainable added value to each project it takes on, while generating revenue from the sale of EAWD Off-Grid AWG Systems, EAWD Off-Grid EV Charging Stations, EAWD Off-Grid Power Systems and EAWD Off-Grid Water Purification Systems; royalties from the commercialization of energy and water in certain cases; and licensing of its innovated technologies, along with its engineering, technical consulting and project management services.

EAWD continues to be a development stage company. It presently assembles its EAWD Off-Grid AWG Systems and EAWD Off-Grid EV Charging Stations at its workshop in Germany and outsources most of its engineering and technical services, as well as services relating to the promotion, sale and distribution of its products.

Market Opportunity

According to a report by Allied Market Research, a global market research, consulting and advisory firm, the worldwide green technology and sustainability market was valued at $10.32 billion in 2020 and is projected to reach a value of $74.64 billion by 2030, growing at a CAGR of 21.9% during the forecast period.

A surge in environmental awareness and increasing concerns among organizations and individuals about climate change drive the growth of the market. Furthermore, an increase in consumer and industrial interest for the use of clean energy resources are among some of the major factors expected to boost growth of the market in the coming years, according to the report.

The expected rise in favorable government and private initiatives to tackle climate change and air pollution represent an opportunistic factor of the market. An increase in energy consumption and rise in greenhouse gas emissions are major factors that drive the development of green technology innovations, the report states.

Management Team

Irma Velazquez is CEO and Vice Chair at EAWD. She brings certified expertise in sustainable development and large-scale project management to the company. She formerly worked for United Nations agencies including the World Health Organization, Farmaciens Sans Frontieres, Red Cross and Crescent Societies, where she served in the positions of Information Technology Manager, Sustainable Development Manager, Programme Manager and Disaster and Crisis Management Coordinator. She has a master’s in sciences from the Erasmus University of Rotterdam. She speaks French, English and Spanish.

Ralph Hofmeier is Chief Technology Officer and Chairman at EAWD. He brings a mechanical engineering background to the company and previously served as President of Powermax Energy & Business Solutions Inc. When that company merged with EAWD, he served as President and CEO of Directors of EAWD. Over the last 20 years, he has established and developed several multinational companies in green tech distribution and commercialization. He speaks German and English.

Energy and Water Development Corp. (OTCQB: EAWD), closed Tuesday's trading session at $0.0014, up 16.6667%, on 300,800 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.0012/$0.12.

Recent News

Calidi Biotherapeutics Inc. (NYSE American: CLDI)

The QualityStocks Daily Newsletter would like to spotlight Calidi Biotherapeutics Inc. (NYSE American: CLDI).

Calidi Biotherapeutics (NYSE American: CLDI) presented data at the International Oncolytic Virotherapy Conference and the Society for Immunotherapy of Cancer Annual Meeting highlighting its RTNova™ systemic virotherapy technology. This innovative platform leverages a tumor-selective vaccinia virus enhanced with extracellular enveloped viruses ("EEVs") to overcome challenges like immune clearance and limited targeting in systemic virotherapy. RTNova demonstrated potential to target and kill metastatic tumor sites across multiple oncology indications, including metastatic lung cancer, while transforming tumor microenvironments and delivering therapeutic payloads. These findings position RTNova as a groundbreaking approach for addressing advanced metastatic diseases, supporting Calidi's mission to develop multi-modal, off-the-shelf virotherapies for a broader patient population.

To view the full press release, visit https://ibn.fm/REQoD

Calidi Biotherapeutics Inc. (NYSE American: CLDI) is a clinical-stage immuno-oncology company pioneering proprietary technology that empowers the immune system to combat cancer. Calidi’s innovative, off-the-shelf cell-based platforms use allogeneic stem cells to deliver potent oncolytic viruses (OVs) across multiple oncology indications, including high-grade glioma (brain cancers) and solid tumors. In addition, Calidi has presented a breakthrough systemic technology, RTNova, which utilizes an exteracellular enveloped virotherapy. RTNova is pre-clinical and has been extremely well-received by market analysts and large-cap biopharma – opening the door for potential collaboration.

These cell-based platforms are engineered to protect, amplify, and enhance the efficacy of oncolytic viruses, resulting in improved patient safety and potentially advancing treatment outcomes for metastatic disease. By employing a dual approach that combines OV delivery with immune activation, Calidi’s therapies aim to not only treat but potentially prevent the spread of metastatic cancers.

The company’s development pipeline leverages this technology to address pressing needs in cancers such as glioblastoma (brain cancer), metastatic melanoma, triple-negative breast cancer, head & neck cancer, and lung cancer. Calidi’s approach has shown early signals of efficacy and safety, establishing it as a distinctive player in the growing OV market, which is projected to increase significantly in value over the next decade.

Calidi is headquartered in San Diego, California.

Products

Calidi’s product pipeline includes advanced cell-based platforms targeting a variety of oncology indications, each designed to harness the power of oncolytic virotherapy for improved cancer treatment outcomes.

  • NeuroNova (CLD-101): A platform designed for treating high-grade gliomas (HGG), NeuroNova employs neuronal stem cells combined with an engineered adenovirus (CRAD-s-Pk7) to selectively target glioma cells. After a successful Phase 1 safety study in newly diagnosed HGG, NeuroNova has now progressed into Phase 1/1b trials for recurrent cases. FDA clearance for a Phase 1b/2 trial at Northwestern University was received in September 2024, with patient enrollment expected to begin in Q1 2025. This trial will utilize multiple-dose intracerebral administration to maximize safety and efficacy in newly diagnosed HGG patients.
  • SuperNova (CLD-201): Built on Calidi’s foundational technology, SuperNova utilizes an engineered Vaccinia virus (CAL1) delivered via allogeneic adipose-derived mesenchymal stem cells to target advanced solid tumors, including head & neck, triple-negative breast cancer, and soft tissue sarcomas. Early studies with autologous stem cells demonstrated both safety and promising efficacy, and Calidi plans to begin a Phase 1 trial with multiple dose regimens for SuperNova in the coming months.
  • RTNova (CLD-400): Calidi’s systemic delivery platform for lung and metastatic cancers, RTNova employs an extracellular enveloped virotherapy (envRT-01) technology for intravenous (IV) administration, simplifying the treatment process and expanding its potential applications. Currently in preclinical stages, RTNova focuses on demonstrating efficacy and safety through systemic administration. A clinical trial targeting metastatic lung cancer is anticipated for Q2 2026, using a single-arm monotherapy with dose escalation. Calidi has partnered with SIGA Technologies (NASDAQ: SIGA) to support the development of this program.

Market Opportunity

The global oncology drugs market was valued at $201.75 billion in 2023 and is projected to grow to $518.25 billion by 2032, with a CAGR of 11.3%. The oncolytic virotherapy market in particular is growing rapidly, driven by increasing approval rates and significant unmet needs.

The market for OV treatments is expected to expand from one approved product generating $150 million in the U.S. in 2021 to 6-8 approved therapies generating $2.4 billion by 2030. As a leader in OV technology, Calidi is well-positioned to address these high-demand areas in oncology.

Alongside global trends, the American Cancer Society projects nearly two million new cancer diagnoses in the U.S. in 2024, reflecting a 28% increase since 2010. This underscores the urgent need for novel therapies that not only treat disease progression but also enhance patient quality of life, reinforcing the demand for Calidi’s innovative approaches.

Management Team

Allan Camaisa, CEO, Chairman, and co-founder, is a seasoned leader with extensive experience in scaling businesses to successful exits. Mr. Camaisa previously led High Technology Solutions, growing it from two employees to over 500 with $50 million in revenue. He also served as CEO of Parallel6 Inc. and is a U.S. Naval Academy graduate with further studies at Harvard Business School.

Antonio Santidrian, Ph.D., Chief Scientific Officer, leads all research and development initiatives at Calidi and is the coinventor of the company’s CLD-201 (Supernova) and CLD-400 (RTNova) platforms. Since joining Calidi in 2015, he has applied his 20+ years of expertise in academia and biotech, focusing on anti-cancer translational research, to drive the company’s innovative drug pipeline. Before Calidi, Dr. Santidrian led translational studies at The Scripps Research Institute, advancing treatments for breast cancer metastasis, and contributed to the development of ACADRA for chronic lymphocytic leukemia (CLL) at the University of Barcelona, Spain.

Boris Minev, M.D., President of Medical and Scientific Affairs, is a renowned physician-scientist with expertise in Immuno-Oncology, stem cell biology, and oncolytic viruses. Previously, Dr. Minev served as Director of Immunotherapy and Translational Oncology at Genelux Corporation and remains an adjunct professor at the Moores UCSD Cancer Center. His background includes research at the National Cancer Institute.

Andrew Jackson, CFO, has held executive finance roles with experience in biotech and clinical-stage companies, including Eterna Therapeutics and Ra Medical Systems. Mr. Jackson holds an MSBA in Finance from San Diego State University and a BSB in Accounting from the University of Minnesota.

Calidi Biotherapeutics Inc. (NYSE American: CLDI), closed Tuesday's trading session at $2.4, up 2.1277%, on 2,256,213 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.73/$26.30.

Recent News

Coyuchi Inc.

The QualityStocks Daily Newsletter would like to spotlight Coyuchi Inc.

The International Organization for Standardization (ISO) recently announced new Environmental, Social, and Governance (ESG) principles at this year's U.N. Climate Change Conference. These implementation guidelines align with the organization's commitment to climate action and the United Nations Sustainable Development Goals. These guidelines will mainly focus on assisting companies to navigate the ESG landscape, with their primary objective being to make it easy to comply with disclosure requirements while improving the communication, reporting, and measurement of sustainability efforts. The British Standards Institution's Chef Executive, Susan Taylor Martin, explained that the guidelines would also help society drive actual change in areas like biodiversity protection and reduction of emissions, ultimately accelerating progress towards a sustainable world. Individuals wishing to learn more about the implementation principles can visit iso.org/ESGprinciples. These global guidelines are likely to help numerous entities, such as Coyuchi Inc., to have a better way of collecting and making use of the data they collect while implementing different ESG principles.

Coyuchi is the gold standard in sustainable luxury home goods. The company offers sustainably produced luxury organic bedding, sheets, towels, apparel, and other home goods for the environmentally conscious home. With a timeless, coastal-inspired aesthetic, Coyuchi uses only 100% organic cotton materials to manufacture all of its textiles.

The Company was built upon four foundational pillars: protect the planet, innovate circular design, live sustainably, and enrich the community. These guiding principles have proven an effective market strategy. In 2021, Coyuchi earned $33.3 million in net sales, amounting to 26% YoY growth (the industry average is only 5%). It also experienced 2x customer growth to 200,000 active customers, averaging a 35% customer repeat purchase rate.

With a seasoned leadership team, a robust e-commerce shopping experience, and a healthy customer base that drives the fast-growing organic luxury market, Coyuchi is prepared to propel a new phase of growth as the rest of the world finally awakens to sustainability at scale.

A Lucrative Market Ripe for the Taking

The global market for organic bedding, which was estimated at $814.3 million in 2020, is projected to reach $1.1 billion by 2027, growing at a CAGR of 4.9% over that period, according to Research and Markets. More specifically, the domestic organic bedding market is estimated at $240.1 million in 2020, according to Statista. Overall, the U.S. market for home textiles is currently valued at $25 billion annually, and, with a forecast annual growth rate of 5%, it is expected to reach $30 billion by the end of 2025.

Grand View Research reported in 2020 that shifting consumer preference toward high-end lifestyle products is a key factor driving the growth of the organic bedding market. Seventy-four percent of consumers are willing to pay more for sustainable products – a consumer preference that has steadily increased over the last few decades. Millennials especially favor ethical consumption over price when purchasing goods and services, with 83% of millennials reporting that they want the brands they purchase from to align with their beliefs and values (https://ibn.fm/PANNV). With a majority millennial customer base, Coyuchi is poised to capitalize on this trend.

Industry Defining Sustainability Practices

For 30 years, Coyuchi has explored organic farming and sustainable textiles and guarantees the highest environmental and ethical standards through a number of certifications such as The Global Organic Textile Standard (GOTS), Fair Trade Certified, and MADE SAFE®.

Coyuchi continues to push the organic textile market forward through its circularity initiatives and by supporting cross-industry sustainability advocates. Coyuchi’s mission to bring beauty and comfort to every home without sacrificing the health of our planet has resulted in a number of important sustainability checks and balances.

  • A Circular Business Model: Coyuchi has cultivated a holistic 360-degree approach that contributes to the fight against climate change with its take back and recycling program, 2nd Home™. In 2017, it became the first luxury home brand to implement such an initiative, and, since then, the company has eliminated 68,758 lbs. of toxic chemicals from homes and renewed 6,000 lbs. of textiles.
  • The Coyuchi Climate Council: In early 2022, Coyuchi introduced a cross-disciplinary council with a goal of Net Zero Emissions by 2025 and Net Positive Emissions by 2030. The Coyuchi Climate Council brings together influential minds across fashion, regenerative farming, and sustainability who have the knowledge and experience necessary to achieve climate change.
  • C4: The California Cotton & Climate Coalition: Most recently, Coyuchi announced it is a founding member of C4, which includes innovative, sustainable fashion, apparel, and personal care brands like MATE the Label, Outerknown, Reformation, and Trace. Working together pre-competitively, C4 creates a structure for investing in regionally grown, Climate Beneficial™ cotton and directly supports the livelihoods of the farmers that grew it. Coyuchi is the only home industry brand currently involved in the project.

Omnichannel Business Model

Coyuchi differentiates itself through an omnichannel and circular business model, both of which have proven a clear draw for customers. It was an early adopter of an e-commerce sales and marketing approach (over 80% of its sales are directly through coyuchi.com), creating a distinct advantage over incumbents and start-up newcomers in the luxury space. This has resulted in a high lifetime value customer, luxury retail partners such as Nordstrom, and a flagship store in Marin County.

Coyuchi’s Organic Textile Products

Coyuchi’s product assortment consists of consciously designed bedding, bath, apparel, and lifestyle products spread across about 1,400 SKUs. The company believes that its product assortment, produced from 100% organic cotton with Global Organic Textile Standard (GOTS) certification, provides it with a significant competitive advantage. GOTS is the world’s leading textile processing standard for organic fibers, ensuring the organic status of textiles after harvesting raw materials through environmentally and socially responsible manufacturing all the way to labeling, a major environmental and social benefit over conventional cotton product production.

Coyuchi’s focused product assortment consists of four core categories:

  • Bedding – A full suite of sustainable, organic, and high-quality sheets, duvet covers, blankets, and throws.
  • Bath – A luxurious line of towels, bath rugs, and mats.
  • Apparel – Premium apparel for men and women, including robes, sweaters, pants, and pajamas.
  • Lifestyle – The lifestyle category offers 135 SKUs, from organic napkins to crossbody totes.

Management Team

Eileen Mockus is President and CEO at Coyuchi. She has more than 25 years of experience in retail, having held positions in textile development at Patagonia, Pottery Barn Teen, and The North Face. She earned a bachelor’s degree in textiles and clothing from UC Davis and an MSBA from San Francisco State University.
Sejal Solanki is Chief Marketing Officer at Coyuchi. She previously served as the company’s Vice President of E-Commerce. Before joining Coyuchi, she worked at teen clothing giant Charlotte Russe. She oversees the company’s digital marketing, site experience, brand marketing, and e-commerce strategy.

Marcus Chung is Coyuchi’s COO, overseeing supply chain, sourcing strategy, sustainability, and IT. He previously held positions at notable direct-to-consumer brands Third Love and Stitch Fix, as well as national retailer The Children’s Place. He holds a bachelor’s degree from Wesleyan University and an MBA from UC Berkeley’s Haas School of Business.

Margot Lyons is Director of Sustainability and Sourcing at Coyuchi, where she works with strategic partners to ensure all the company’s product sustainability standards are met. She received a master’s degree in textiles and clothing from UC Davis.

Use of Proceeds

This round of funding will be used to increase Coyuchi’s enterprise value through expanded marketing, product category expansion, continued physical presence, and B2B strategic partnerships with wholesalers, and online marketplaces.

Recent News

chart

SportLync Inc.

The QualityStocks Daily Newsletter would like to spotlight SportLync Inc.

SportLync, recognizing that finding the right players with which to compete or simply enjoy a friendly round of golf can make a huge difference, recently introduced the Top Player Lyncs feature in its GolfLync app. The powerful tool is designed to bring golfers together based on skill level, interests and location. "Top Player Lyncs is an exclusive feature within the GolfLync app that enables users to view and connect with their most compatible matches in their area," reads a recent article. "Whether you're a beginner looking for a partner, or an experienced golfer seeking a challenge, Top Player Lyncs ensures you find the right people to match your needs. It's all about creating stronger connections and making it easier than ever to build a local golfing network and improve your skills."

To view the full article, visit https://ibn.fm/yn6EG

SportLync Inc. matches golfers looking for a game through the company’s smartphone app, GolfLync. The company bills GolfLync as the “Tinder for Golf,” matching golf games and players similar to the way a dating app matches those looking for romance.

The app allows like-minded golfers to connect for a game simply by logging in. GolfLync helps golfers who are looking to grow their golf network find other players with similar interests and on course preferences. Whether you have recently moved to a new area and are looking for new golfing buddies, travel frequently and would like to play a round of golf while on the road, or just want to meet new golfers in your area, GolfLync is your answer. Spouses who enjoy golfing together can find other golfing couples to tee it up with. For a regular group that finds itself unexpectedly down a player, GolfLync can help find that last-minute addition to complete the foursome.

The company is based in Scottsdale, Arizona.

GolfLync App

GolfLync was created for golfers of all skill levels and preferences to connect with compatible players of similar skill and interests. Golfers can find a tee time through GolfLync, join existing tee times and create new leagues. The app allows golfers to meet fellow players before committing to spend four hours on the course with them. GolfLync allows users to find new golf friends based on their preferences, such as walking or riding a cart, listening to music, friendly wagering, imbibing a favorite beverage at the 19th Hole and more. GolfLync is available for both Android and iOS as a free download.

Download on Apple App Store   Get it on Google Play

 

Market Opportunity

According to a report by Statista, a leading provider of market and consumer data, in 2022, the number of people participating in golf in the United States reached 25.6 million, with 15.5 million additional players participating in off-course activities like driving ranges. In 2020, over 502 million rounds of golf were played in the U.S. alone. The game, traditionally dominated by male players, is changing, with increased interest from women golfers driven by social media influencers around the game.

Lumen Sports puts the total number of golf courses in the U.S. at more than 16,700. According to Lumen, about 75% of those are public courses open to all golfers, with the rest considered private golf clubs that require a membership.

 

Management Team

Noah DiPasquale is a co-founder and CEO of SportLync Inc., leading the marketing and operations of the platform. He is also the founder and CEO of Epic Golf Club, a premier national membership and private golf society which partners with hundreds of top tier private golf clubs allowing Epic members access to their courses and recently founded the Epic Foundation, a Scottsdale-based 501c3. He holds a B.S. in Business Administration, Management and Operations from the W.A. Franke College of Business at Northern Arizona University and an MBA in Marketing from the University of Phoenix.

Michael Quiel is a co-founder of SportLync Inc. and the President of the organization. He leads the application development and research teams. Michael understands how to build successful companies. His deep knowledge of investment banking, finance and building successful business partnerships is unparalleled. He’s an expert at capital formation and growth hacking companies. He has raised over $250 million in capital and taken multiple companies public.

Recent News

chart

Torr Metals Inc. (TSX.V: TMET)

The QualityStocks Daily Newsletter would like to spotlightFathom Torr Metals Inc. (TSX.V: TMET) .

Since 2024 began, interest in gold investing has increased significantly, driven largely by the metal's price surging over the last few months. Over the last ten months, gold's price has risen to new highs while attracting even more investors and breaking prior records. Some analysts forecast that the metal's price may hit $3000 an ounce before the year ends, based on its current trajectory. However, it is also important for investors to keep in mind that the price of gold can just as easily start dropping. This month, the precious metal's price has dropped to $2560.90 an ounce, quite a decrease from its high of $2736.35 an ounce. It is important to keep in mind though that the recent decline in gold's price doesn't automatically signal a long-term trend. Exploring several gold stocks like Torr Metals Inc. (TSX.V: TMET) could give you a practical feel of what it means to select firms in which to invest in order to benefit from gold's price movements.

Torr Metals Inc. (TSX.V: TMET) operates as a mineral exploration company focusing on the identification, acquisition, and advancement of mineral properties. With full 100% ownership of over 1,000 square kilometers of gold and copper projects strategically positioned in premier low-cost mining jurisdictions, Torr is poised for substantial returns across various promising regions.

The company’s extensive portfolio encompasses multiple district-scale projects, including the Filion Gold Project in northern Ontario, the Kolos Copper-Gold Project in south-central British Columbia, and the Latham Copper-Gold Project in northern British Columbia. These projects are all located in prolific mining regions with paved highway access, robust support infrastructure, and favorable geological conditions offering significant potential for new discoveries.

Headquartered in Vancouver, British Columbia, Torr Metals is ideally situated to leverage its expertise and resources for continued exploration and growth.

Projects

Kolos Copper-Gold Project

Situated within British Columbia’s prime copper-producing belt, the 140-square-kilometer Kolos Copper-Gold Project exhibits Nicola Belt geology similar to notable porphyry mines, including Copper Mountain and Highland Valley, respectively situated 106 kilometers to the south and 30 kilometers to the northwest.

With field operations based in the nearby city of Merritt and year-round access provided via Highway 5, the Kolos Project showcases substantial discovery upside potential with five defined large-scale copper-gold-molybdenum anomalies untested by drilling.

Torr Metals’ primary focus lies in unlocking the potential for major new discoveries at the Kolos Copper-Gold Project, with recent surface geochemical results marking a significant milestone positioning the company as a new key player in the region.

Filion Gold Project

The 261-square-kilometer Filion Project is situated within a largely unexplored greenstone belt where gold was initially discovered in the 1930s. With a comparable geological setting to regional orogenic gold deposits and multiple newly identified and undrilled gold trends in surficial geochemistry, the Filion Project holds significant district-scale exploration promise.

The Filion Project benefits from unparalleled infrastructure access, with direct drive-on access from the Trans-Canada Highway, as well as a regional railway and power grid four kilometers to the south. Additionally, the nearby town of Kapuskasing, with a population of 8,300, provides essential support services.

This strategic positioning ensures the Filion Project’s viability for cost-effective, year-round operations in an area poised for untapped discovery potential.

Latham Copper-Gold Project

Situated in British Columbia’s renowned Golden Triangle, the Latham Project spans a vast 689-square-kilometer district, offering immense potential for multiple major discoveries. Accessible year-round via Highway 37, just 20 kilometers south of the town of Dease Lake, the site is strategically located amidst established mining infrastructure, including the active Red Chris mine to the southeast and upcoming major porphyry projects at Schaft Creek and Galore Creek along-trend to the southwest.

Highlighted by the Gnat Pass copper-gold porphyry deposit dating back to the 1960s, the Latham Project presents a compelling opportunity for significant expansion and potential discovery. A non-compliant indicated resource at the Gnat Pass deposit includes 33 million tonnes at 0.39% copper, open beyond 200 meters vertical depth, alongside six drill-ready kilometer-scale copper-gold exploration targets.

Moreover, the Latham Project’s appeal corresponds to the region being an attractive destination for major asset acquisitions and takeovers. Recent transactions within a 40-kilometer radius include Newmont’s 2021 acquisition of the Saddle North copper-gold porphyry deposit for $311 million and Newcrest’s investment in the Red Chris copper-gold porphyry deposit in 2019 for $804 million, underscoring industry acknowledgment of the region’s potential.

Market Opportunity

The World Gold Council, the industry association for the world’s gold producers, estimated in 2023 that the physical financial gold market, which is made up of bars, coins, gold ETFs and central bank reserves, is worth nearly $5 trillion.

The council reports that gold mine production adds approximately 3,500 tons of the precious metal to the world’s supply annually, equivalent to about 2% growth. This historical scarcity and relatively slow production of new supply, as compared to other commodities, is a primary reason gold has retained its value for millennia, according to the council.

Likewise, a report from Acumen Research and Consulting, a global provider of market intelligence and consulting services, valued the global copper market at $304.1 billion in 2022 and forecast that it will reach a market size of $496.8 billion by 2032, growing at a CAGR of 5.1% over the forecast period.

The report identifies a growing demand for copper in the electronics industry, as well as an expanding copper supply due to increasing production from existing mines and the rising number of mine development projects in developing nations, as driving factors in the rising value of the copper market.

Management Team

Malcolm Dorsey, P.Geo., is President, CEO and Director of Torr Metals. He brings over a decade of expertise as a seasoned exploration geologist and project developer, having been pivotal in driving the success of numerous diverse projects across North, Central, and South America. His comprehensive background spans early-stage exploration through to resource development and project acquisitions. His academic credentials include an M.Sc. in Geology and Geophysics from the University of Calgary, where his research characterized the district-scale structural influences affecting copper and gold mineralizing events in western British Columbia. Prior to his current role, he served as Senior Geologist for Benchmark Metals, where his contributions were instrumental in advancing the company’s gold equivalent resource from approximately 80,000 ounces to a maiden resource estimate of 2.92 million ounces.

John Williamson, P. Geol., is Chairman and Director of Torr Metals. He is a mining executive and investor with more than 30 years of experience as a founder, promoter and leader in the formation, financing and operation of private and public companies with exploration and mining interests worldwide. On more than one occasion his team’s efforts have been recognized for excellence by being named to the TSX Venture 50. He holds a B.Sc. in Geology and is a registered Professional Geologist (P.Geol.) with the Association of Professional Engineers and Geoscientists (APEGA) and the Geological Association of Canada.

Torr Metals Inc. (TSX.V: TMET), closed Tuesday's trading session at $0.09, even for the day. The average volume for the last 3 months is and the stock's 52-week low/high is $0.035/$0.195.

Recent News

Annovis Bio Inc. (NYSE: ANVS)

The QualityStocks Daily Newsletter would like to spotlight Annovis Bio Inc. (NYSE: ANVS).

Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company focused on developing transformative therapies for neurodegenerative disorders, including Alzheimer's disease ("AD") and Parkinson's disease ("PD"), recently achieved a significant milestone in its drug development process. In early October, the company held a meeting with the U.S. Food and Drug Administration ("FDA"), where it received clearance to proceed with pivotal Phase 3 studies for its lead compound, buntanetap.

"We are now ready to move into the highly anticipated Phase 3 stage," Maria Maccecchini, Ph.D., founder, president and CEO of Annovis Bio, was quoted as saying. "Our priority is to bring the treatment to patients as early as possible, and we are executing the next clinical trial at the highest standards to attain an expedited NDA submission."

To view the full article, visit https://ibn.fm/qSTrA

Annovis Bio Inc. Overview

Annovis Bio Inc. (NYSE: ANVS) is a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as AD and PD. Annovis Bio stands out by developing a drug that targets multiple neurotoxic proteins simultaneously, aiming to restore axonal and synaptic activity. This innovative approach addresses both the cognitive decline in AD and the motor dysfunction in PD, making Annovis a unique player in the neurodegeneration space.

Lead Drug Candidate: Buntanetap

Buntanetap (formerly known as Posiphen) targets neurodegeneration by inhibiting the formation of multiple neurotoxic proteins, including amyloid beta, tau, alpha-synuclein, and TDP43. This multifaceted inhibition improves synaptic transmission and axonal transport, reduces neuroinflammation, and protects nerve cells from dying. Unlike monoclonal antibody therapies, buntanetap is an orally available small molecule capable of inhibiting multiple neurotoxic proteins at once, positioning it as a comprehensive solution for neurodegenerative diseases.

In a recent Phase II/III Alzheimer’s study, buntanetap demonstrated statistically significant efficacy. Patients with early AD showed a significantly higher rate of improvement in ADAS-Cog 11 scores across all treatment doses compared to placebo, with a 3.3 point improvement compared to 0.3 for placebo (p < 0.01). Plasma Tau protein levels also reduced, consistent with previous Phase II biomarker data, further validating buntanetap’s mechanism of action.

Similarly, in the recently completed Phase III study of buntanetap in patients with early PD, buntanetap significantly improved disease-related daily non-motor and motor functions in Parkinson’s patients who had a diagnosis over 3 years as well as improved cognition in all PD patients. It further underscores buntanetap’s potential as a transformative therapy.

Market Opportunity

The aging population presents a significant market opportunity, with nearly 7 million Americans currently suffering from Alzheimer’s Disease (AD), a figure projected to rise to almost 13 million by 2050​ (Alzheimer’s Association)​​ (Republican Policy Committee)​. Additionally, approximately 1.2 million people in the U.S. have Parkinson’s Disease​ (SingleCare)​.

The economic burden of Alzheimer’s is immense, with care costs expected to reach $360 billion in 2024 and escalate to nearly $1 trillion annually by 2050​​. The need for effective, comprehensive treatments like Buntanetap is more critical than ever.

Company Highlights

  • Innovative Therapeutic Approach: Annovis Bio uniquely targets multiple neurotoxic proteins, aiming to restore nerve cell health and improve cognitive and motor function in AD and PD patients.
  • Robust Clinical Data: Phase II/III studies show significant improvements in cognitive function and biomarker levels in early AD patients.
  • Groundbreaking Clinical Insights: Recent Phase III data in Parkinson’s Disease patients demonstrates significant improvements in motor and cognitive functions.
  • Upcoming Phase III Trials: Plans are underway for an 18-month Phase III trial focusing on biomarker-positive early AD patients, designed to further validate buntanetap’s disease-modifying potential.
  • Capital Efficiency: Annovis Bio is capital-efficient, with zero debt and multiple global patents extending into the 2040s.

Management Team

  • Maria L. Maccecchini, Ph.D. – Founder, President, CEO, and Executive Board Member, founded Annovis Bio in May 2008 with the mission to develop better therapeutics for Alzheimer’s, Parkinson’s, and other neurodegenerative diseases. She has previously been a partner and director at two angel groups, Robin Hood Ventures and MidAtlantic Angel Group, and founded Symphony Pharmaceuticals/Annovis, which was sold to Transgenomic in 2001. Her extensive experience includes roles such as General Manager at Bachem Bioscience and Head of Molecular Biology at Mallinckrodt. Dr. Maccecchini holds a Ph.D. in biochemistry from the Biocenter of Basel, with postdoctoral work at Caltech and the Roche Institute of Immunology.
  • Cheng Fang, Ph.D. – Senior VP of Research and Development, is an accomplished neuroscientist with two decades of experience in neurodegenerative diseases. She has a successful track record of scientific publications and contributions, coupled with extensive pre-clinical and clinical development experience. Dr. Fang has been instrumental in advancing the understanding of neurodegenerative disease mechanisms and developing therapeutic strategies.
  • Michael Christie, Ph.D. – VP of Process Chemistry, has over 40 years of experience in the pharmaceutical industry, focusing on process chemistry R&D, pilot plant production, and GMP operations. He has held senior management positions at companies such as SmithKline, Rhodia, Teva, and Cephalon, and founded a contract process R&D service company, which was later acquired by ChiRex. Dr. Christie is co-author or co-inventor on several publications and patents. He earned his BS in chemistry from the University of Michigan and his doctorate from MIT.
  • Melissa Gaines – Senior VP of Clinical Operations, is an accomplished clinical research professional with over 20 years of experience across academia, contract research organizations, and pharmaceutical companies. She has proven abilities in monitoring and managing Phase I to IV clinical trials, specializing in CNS disorders and extending to a broad range of therapeutic indications. Her CNS experience spans from small Phase I and II studies to large global Phase III trials in Alzheimer’s disease, Parkinson’s disease, sleep disorders, and various psychiatric diseases in both adult and pediatric populations. In her current role, she oversees and supports all clinical project activities, driving operational success and ensuring high-quality clinical outcomes.
Recent Achievements

Annovis Bio continues to advance its mission of developing transformative therapies for neurodegenerative disorders. The company recently announced statistically significant data from its Phase II/III Alzheimer’s study, demonstrating the potential of its lead drug candidate, buntanetap, to improve cognition in patients with early Alzheimer’s Disease (AD). Additionally, the company has released promising data from its Phase III study of buntanetap in patients with early Parkinson’s Disease (PD), which highlights significant advancements in both cognitive and motor functions. These milestones underscore the expanding therapeutic reach of buntanetap.

Investment Considerations
  • Unique Market Position: Annovis Bio is uniquely positioned as the only company developing a drug for both AD and PD that inhibits multiple neurotoxic proteins simultaneously.
  • Strong Clinical Results: Buntanetap’s Phase II/III data shows significant cognitive improvement in early AD patients, and the recent Phase III data in PD patients further validates its broad therapeutic potential.
  • Strategic Growth Plans: With recent successful trial results, Annovis Bio is poised for future growth, supported by strong patent protections and upcoming clinical trials.
  • Significant Market Need: As the prevalence of neurodegenerative diseases continues to rise, the demand for effective treatments like buntanetap remains critical.

Annovis Bio continues to advance its mission of developing transformative therapies for neurodegenerative disorders. The company recently announced statistically significant data from its Phase II/III Alzheimer’s study, demonstrating the potential of its lead drug candidate, buntanetap, to improve cognition in patients with early Alzheimer’s Disease (AD). Additionally, the company has released promising data from its Phase III study of buntanetap in patients with early Parkinson’s Disease (PD), which highlights significant advancements in both cognitive and motor functions. These milestones underscore the expanding therapeutic reach of buntanetap.

Annovis Bio Inc. (NYSE: ANVS), closed Tuesday's trading session at $6.68, off by 2.0528%, on 139,518 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $4.53/$22.49.

Recent News

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI)

The QualityStocks Daily Newsletter would like to spotlight Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI).

New research by scientists from the Oregon Health & Science University and Johns Hopkins Kimmel Cancer Center has found a new approach that can make tumors resistant to immunotherapy vulnerable to the treatment. For their study, the researchers evaluated the effectiveness and safety of the combination of 2 medications; entinostat, an epigenetic drug; and nivolumab, an immunotherapy medication. The drugs were administered to a group of twenty-seven patients with advanced pancreatic ductal adenocarcinoma. The patients had in the past undergone chemotherapy. The study's findings were reported in Nature Communications. The study was supported by the National Institutes of Health and the National Cancer Institute, among other institutions. This additional information from this study about how to combat resistance to immunotherapy promises to expand the range of applicability of immunotherapies developed by companies like Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) targeting different malignancies.

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) is a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious diseases and autoimmune diseases.

In collaboration with the prestigious Max Planck Institute for Multidisciplinary Sciences (MPG) and the University Medical Center Göttingen (UMG), both in Germany, Scinai is developing a pipeline of innovative nanosized antibody (NanoAb) therapies addressing diseases underserved by current treatments and with large and growing markets, such as COVID-19, asthma and psoriasis.

NanoAbs, also known as VHH-antibodies or Nanobodies, are alpaca-derived nanosized antibodies that exhibit multiple significant competitive advantages over existing antibody therapies, including stability at high temperatures, superior binding affinity, more effective and convenient routes of administration and efficient production. Scinai is uniquely positioned to advance nanosized antibody innovation from R&D through commercialization.

The company’s highly experienced and successful pharmaceutical industry leadership team includes former senior executives from Novartis, GSK and Bristol-Myers Squibb.

Since its founding, Scinai has executed eight clinical trials, including a seven-country, 12,400-participant Phase 3 trial of a prior influenza vaccine candidate, and it built, owns and operates a 20,000 sq. ft. state-of-the-art GMP biologics manufacturing facility housing its laboratories, production facilities and offices.

Lead Candidate: Inhaled COVID-19 NanoAb

In December 2021, Scinai signed definitive agreements with the Max Planck Society – parent organization of the Max Planck Institute for Multidisciplinary Sciences– and the UMG to enter a strategic collaboration for the development and commercialization of innovative COVID-19 NanoAbs.

The company is planning a rapid development path that leverages its expertise and capabilities in biological drug development and manufacturing. Scinai anticipates preclinical proof-of-concept results for an inhaled COVID-19 NanoAb by the end of 2022, with initial Phase 1/2a human clinical trial results expected in 2023.

The intended inhaled mechanism of delivery of Scinai’s COVID-19 NanoAb formulation may serve as a significant differentiator when compared to approved monoclonal antibodies, which are injected. Inhaled delivery has shown to be cheaper, more convenient and likely safer for patients and providers.

NanoAb Pipeline: Psoriasis, Asthma and More

The COVID-19 NanoAb development agreement is part of a broader five-year research collaboration agreement signed in March 2022 covering discovery, development and commercialization of NanoAbs for several other disease indications with large market medical needs, including asthma, psoriasis, macular degeneration and psoriatic arthritis.

Scinai has an exclusive worldwide license for development and commercialization of COVID-19 NanoAbs and exclusive options for similar worldwide licenses for NanoAbs for the above mentioned additional large market disorders currently underserved by approved therapeutic antibodies.

Academic research teams from MPG and UMG have verified strong affinity by the new NanoAbs to their biological target molecules and high thermostability. They have also demonstrated strong neutralization by several NanoAb candidates of their respective target molecules. Neutralization studies of the other NanoAbs are expected to begin later in 2022.

Based on the promising results, Scinai will focus development efforts beginning with the following NanoAbs:

  • NanoAbs targeting IL-17 as drug candidates for the potential treatment of psoriasis and psoriatic arthritis
  • NanoAbs targeting IL-13 and NanoAbs targeting TSLP as drug candidates for the potential treatment of asthma

These are conditions for which the antibody target is validated by existing treatments and the mechanism of action is well understood. Both represent large medical needs and growing markets. Scinai anticipates preclinical proof-of-concept for at least one of these NanoAbs in 2023. This is in addition to the aforementioned human clinical Phase 1/2a for the inhaled COVID-19 NanoAb therapy, which is also anticipated in 2023.

CDMO Services

While NanoAb pipeline development is Scinai’s core focus, the company also offers its cGMP manufacturing facility, aseptic fill and finish suite, laboratories and experienced professionals for contract development and manufacturing organization (CDMO) services. This offering is designed to keep the Scinai team abreast of the latest industry developments and trends while building experience and generating revenue to support the company’s NanoAb pipeline development.

Market Opportunity

COVID-19 treatment, target of the company’s lead NanoAb therapy candidate, had an estimated market size of $22 billion in 2021.

Future Scinai drug candidates will target conditions with large markets growing at attractive CAGRs.

The global asthma treatment market was valued at $18.08 billion in 2019 and is projected to reach $26.01 billion by 2027, exhibiting a CAGR of 4.5% during the forecast period, according to Fortune Business Insights. The research firm predicts that the global psoriasis treatment market will grow from $26.37 billion in 2022 to $47.24 billion by 2029, exhibiting a CAGR of 8.7% over the forecast period.

Management Team

Amir Reichman is Scinai’s CEO. He previously was Head of Global Vaccines Engineering Core Technologies at GSK Vaccines in Belgium. Prior to that, he held leadership roles at Novartis Vaccines’ Global Vaccines Supply Chain Management organization. He was the first employee of NeuroDerm Ltd., a company focused on transdermal drug delivery, and served as Senior Scientist until his departure in 2009. He earned a M.Sc. in Biotechnology Engineering from Ben-Gurion University and an MBA in Finance and Health Care Management from the University of Pennsylvania’s Wharton School.

Tamar Ben-Yedidia, Ph.D., is Chief Science Officer at Scinai. She has more than 30 years of experience in immunology, with specific expertise in the development of vaccines. She began her career with Biotechnology General Ltd., working on development of a recombinant Hepatitis-B vaccine. She later joined the Weizmann Institute of Science, working on the design of a peptide-based vaccine against several pathogens. She is widely published, with numerous refereed articles and invited reviews in various scientific journals. She received her Ph.D. from the Weizmann Institute.

Elad Mark is COO at Scinai. He has over 15 years of biotechnology industry experience encompassing diverse project stages including feasibility studies, conceptual and detailed design, commissioning, qualification and process validation. Prior to joining Scinai, he led Novartis’s $800 million investment in a biologics facility in Singapore. With Biopharmax and Antero, both global pharmaceutical engineering companies, he successfully led projects in Israel, China and Singapore. He holds a BSc. in Engineering from the Afeka Tel Aviv Academic College of Engineering and an MBA from the Open University of Israel.

Uri Ben-Or is CFO at Scinai. He has served as CFO with public life science companies traded on the TASE, OTC and Nasdaq. Ben-Or provides his services to Scinai through CFO Direct, a company he founded and for which he serves as CEO. He served as the VP of Finance of Glycominds, a leading biotechnology company, and as CFO of a spin-off from Telrad Networks. He also served as a Corporate Controller at Menorah Capital Markets and as an Auditor at PWC. He holds a B.A. in Business from the College of Administration, an MBA from Bar-Ilan University, and is a CPA.

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), closed Tuesday's trading session at $2.75, off by 2.1352%, on 11,675 volume. The average volume for the last 3 months is 27,253 and the stock's 52-week low/high is $2.23/$8.92.

Recent News

Life Electric Vehicles Holdings Inc. (OTC: LFEV)

The QualityStocks Daily Newsletter would like to spotlightFathom Life Electric Vehicles Holdings Inc. (OTC: LFEV) .

Kairos Pharma (KAPA) announced its approval for a dual listing on Upstream, a MERJ Exchange market and global securities trading app, with trading set to begin on November 26 under the ticker symbol 'KAPA.' The listing aims to broaden Kairos Pharma's investor base beyond the U.S., enhance liquidity, and facilitate price discovery. Investors can prepare to trade by signing up on Upstream and completing KYC verification. CEO Dr. John Yu highlighted the dual listing as a strategic move to build shareholder value while advancing the company's lead drug, ENV105, for cancer treatment through clinical trials and commercialization.

To view the full press release, visit https://ibn.fm/vpTAl

Life Electric Vehicles Holdings Inc. (OTC: LFEV) (d/b/a Life EV Group), along with its subsidiaries, is a developer, manufacturer and distributor in the light electric vehicle industry. The company’s business model focuses on the launch, acquisition and consolidation of multiple brands of e-bikes, e-trikes, e-scooters and light EVs with the aim of positioning itself as an industry leader for the American micro-mobility market.

The light electric vehicle industry, mainly e-bikes, is fast becoming a leading form of EV sales in the U.S. and Europe. In addition to offering ready-to-ride electric vehicles, Life EV Group intends to distribute individual components, including motors, batteries, chargers, controllers and EV parts, to third party manufacturers in both the U.S. and worldwide.

The company’s first acquisition was completed in 2023 with a 40% equity stake in LEV Manufacturing Inc., a related company and American manufacturer of e-bikes. LEV Manufacturing’s assembly utilizes free-trade zone processes with a U.S. Certificate of Origin, eliminating middle layer costs and resulting in cost-effective production and lower MSRPs.

LEV Manufacturing recently completed the acquisition of Serial 1 Cycle Company LLC. Serial 1 is an e-bike maker founded by U.S. motorcycle manufacturer Harley-Davidson in 2018 and spun off as an independent brand in 2020. The acquisition positions Serial 1 for even greater success and long-term growth.

Life EV Group is headquartered in Deerfield Beach, Florida.

Market Opportunity

An analysis from Mordor Intelligence, a market research and advisory firm, estimates the e-bike market to be worth $34.98 billion in 2024 and projects it will expand to reach a value of $51.78 billion by 2029, representing a CAGR of 8.16% during the forecast period.

Mordor attributes forecast market growth primarily to the increasing adoption of electric bikes as a mode of daily transportation around the world. The market is seeing an upsurge in unit sales based on their attractive consumer characteristics, including health benefits, affordability and convenience.

The North American electric bike market is growing as the preference for low-speed two- and three-wheelers has increased in recent years. Various bike-sharing operators are including electric bikes in their fleets, which is expected to support the sales growth of these bikes in the near future.

Management Team

Robert Provost is the CEO of Life EV Group. He was Founder and CEO of Prodeco Technologies, a maker of e-bikes and e-bike parts and accessories. He also serves as President and CEO of LEV Manufacturing Inc. He is Chairman of the board for Serial 1 Cycle Company.

Daniel Del Aguila is COO at Life EV Group. He co-founded Prodeco Technologies and serves as COO of LEV Manufacturing Inc.

Ivan Drusc is CFO at Life EV Group. He is a seasoned accounting and finance professional with a proven track record in industries from insurance to IT and property management. He has served as a key player in businesses ranging in size from startups to publicly traded global companies. He has experience in cost reduction, risk mitigation, IT and ERP systems, outsourcing and restructuring. He is a graduate of the University of Akron with a bachelor’s degree in accounting.

Life Electric Vehicles Holdings Inc. (OTC: LFEV), closed Tuesday's trading session at $1.47, off by 14.0351%, on 164,688 volume. The average volume for the last 3 months is 424,978 and the stock's 52-week low/high is $1.22/$4.00.

Recent News

GivBux Inc. (OTC: GBUX)

The QualityStocks Daily Newsletter would like to spotlightFathom GivBux Inc. (OTC: GBUX) .

GivBux Inc. (OTC: GBUX) is a publicly traded super app and charitable giving platform. The company is creating a sharing economic community of brands and consumers in which consumers have an easier and more convenient way to shop and buy, merchants have a more efficient and profitable way to advertise, and charities receive built-in contributions from the community’s transactions.

The GivBux Super App revolutionizes shopping by offering a user-friendly tool to make purchases swiftly at over 100 national retailers, along with an expanding roster of local merchants. Users earn cash back on every purchase, a portion of which can be directed toward a charity of their choice, embodying GivBux’s commitment to giving back. Additionally, the app is evolving to include numerous functionalities like social networking, e-commerce, banking, messaging, food delivery and transportation, following the super app model.

GivBux is forging a new path in charitable giving, with aspirations to build the largest community of givers in the United States, and eventually globally. The company believes it is uniquely positioned to make a major contribution to society by overlapping the worlds of commerce and philanthropy.

The GivBux Super App is currently available for free on the Google Play Store and the Apple App Store.

The company is headquartered in Newport Beach, California.

Products

The company, through wholly owned subsidiary GivBux Global Partners Inc., is engaged in the fintech mobile wallet sector, specifically as a point-of-sale payment system by means of a consumer mobile wallet. GivBux uses smartphone technology to bridge consumers and merchants together without the need for traditional plastic cards or paper cash.

The GivBux mobile app has been designed to store, send and receive funds; donate; and make real-time purchases at top retail brands, restaurants and other venues. The brands benefit, because they are empowered with a data-rich marketing tool to reach and retain consumers through their mobile phones.

With GivBux, recipients can use funds instantly by paying with their mobile phones at thousands of locations. GivBux rewards all users for using the app every time they make a purchase and every time their friends, friends of friends and stranger friends make purchases with the GivBux mobile wallet. These rewards can be redeemed for cash to pay at participating retail stores, restaurants, cinemas, entertainment venues and more.

Moreover, GivBux allows users to contribute to a charity or worthy cause of their choice. To encourage giving and recommendations, a trending ‘Top 10 List’ of all charities will be generated and displayed on the mobile wallet based on ongoing contributions by GivBux users.

Market Opportunity

A report from Future Market Insights, a New York-based market research organization, estimated the worldwide mobile wallet market at $9.5 billion in 2023. The report projects that in 2024 the industry is likely to reach a valuation of $11.9 billion, and, by 2034, the mobile wallet market is forecast to grow to a value of $138.5 billion, achieving a CAGR of 27.8% over the forecast period.

Key market growth drivers include payment convenience, transaction security and continuing technological innovation. The report points out that mobile wallet payments are widely accepted worldwide, fueled by a rise in digital transactions and a growing use of mobile phones for simple and effective payment options. Innovations like blockchain integration, contactless payments and artificial intelligence are improving functionality and user experience while staying ahead of rapidly evolving digital payment trends, according to the report.

Management Team

Umesh Singh is President and Director at GivBux. He is a Certified Professional Accountant (Canada) with more than 25 years of experience in accounting and finance. He began his career at PwC before joining Hayes Stuart Little & Company (now Grant Thornton), where he was Senior Accountant-Manager and later Partner. Prior to being named GivBux president, he was a member of the GivBux Advisory Board for more than three years.

Michael Arnkvarn is Vice President of International Business Development at GivBux. He has over 30 years of experience in management, sales and marketing. He managed several medium and large agribusiness and environmental businesses before founding Collagenna Skin Care Products, a natural health products and cosmetics company, in 2004. He has been CEO of multiple public small-cap companies and co-founder of a start-up cannabis company that eventually sold for more than $800 million.

GivBux Inc. (OTC: GBUX), closed Tuesday's trading session at $0.45, up 25%, on 12,118 volume. The average volume for the last 3 months is 1,108 and the stock's 52-week low/high is $0.20005/$1.28.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower
ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers

QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower
ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers

QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower
ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

370 N. Hayden Rd.
Suite 123-591
Scottsdale, AZ 85251
480-374-1336

Please read Disclaimers for FULL Compensation Disclosures and other disclaimers.

Copyright © .